Podcasts about medical science

Before he was even born, Sarah and Ross Gray knew that their son Thomas wouldn't live long. But as they let go of him, they made a decision that reverberated through a world that they never bothered to think about. Years later, after a couple of awkward phone calls, they go on a quest and manage to meet the people and places for whom Thomas' short life was an altogether different kind of gift. We originally made this story back in 2015, but we wanted to play it again because we love that it brings a view of science that is redemptive, tender, and unexpected. Since we first released this episode, Sarah Gray wrote a book called A Life Everlasting (https://zpr.io/GVYisRaqe9d6), it's a memoir about Thomas that dives into the world of organ donation and medical science. She's also written a beautiful short story about shame called The Lacemaker Fairy Tale (https://zpr.io/Li5BMtfHmf92). And, right now she's working on a script for a movie called Raincheck.EPISODE CREDITS: Reported by - Jad Abumrad with help from - Latif NasserLATERAL CUTS - The Cathedral (https://radiolab.org/podcast/cathedral) The Immortal Life of Henrietta Lacks (https://radiolab.org/podcast/the-immortal-life-of-henrietta-lacks)  Signup for our newsletter!! It includes short essays, recommendations, and details about other ways to interact with the show. Sign up (https://radiolab.org/newsletter)! Radiolab is supported by listeners like you. Support Radiolab by becoming a member of The Lab (https://members.radiolab.org/) today. Follow our show on Instagram, Twitter and Facebook @radiolab, and share your thoughts with us by emailing radiolab@wnyc.org. Leadership support for Radiolab's science programming is provided by the Simons Foundation and the John Templeton Foundation. Foundational support for Radiolab was provided by the Alfred P. Sloan Foundation.

The gap between vaccine science and vaccine policy has been widening under Health Secretary Robert F. Kennedy Jr. Now, the American Medical Association and the Vaccine Integrity Project, based at the University of Minnesota, have announced that they are partnering to create their own vaccine review process, effectively creating a parallel system to the CDC's. Host Ira Flatow talks with Michael Osterholm, executive director of the Vaccine Integrity Project, about the role of this new review panel.Guest: Dr. Michael Osterholm is the director of the Center for Infectious Disease Research and Policy and executive director of the Vaccine Integrity Project at the University of Minnesota.Transcripts for each episode are available within 1-3 days at sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.

The use of stimulants during WWII is no secret, but in the last decade, there has been a lot of discussion and analysis of it. Just how significant was drug use in Nazi Germany, and how did the Allies compare? Research: Ackermann, Paul. “Les soldats nazis dopés à la méthamphétamine pour rester concentrés.” HuffPost France. June 4, 2013. https://www.huffingtonpost.fr/actualites/article/les-soldats-nazis-dopes-a-la-methamphetamine-pour-rester-concentres_19714.html Andreas, Peter. “How Methamphetamine Became a Key Part of Nazi Military Strategy.” Time. Jan. 7, 2020. https://time.com/5752114/nazi-military-drugs/ Blakemore, Erin. “A Speedy History of America’s Addiction to Amphetamine.” Smithsonian. Oct. 27, 2017. https://www.smithsonianmag.com/history/speedy-history-americas-addiction-amphetamine-180966989/ Boeck, Gisela, and Vera Koester. “Who Was the First to Synthesize Methamphetamine?” Chemistry Views. https://www.chemistryviews.org/9-who-first-synthesized-methamphetamine/ “Ephedra.” National Center for Complementary and Integrative Health.” https://www.nccih.nih.gov/health/ephedra Eghigian, Greg, PhD. “A Methamphetamine Dictatorship? Hitler, Nazi Germany, and Drug Abuse.” Psychiatric Times. June 23, 2016. https://www.psychiatrictimes.com/view/methamphetamine-dictatorship-hitler-nazi-germany-and-drug-abuse Garber, Megan, “‘Pilot’s Salt’: The Third Reich Kept Its Soldiers Alert With Meth.” The Atlantic. May 31, 2013. https://www.theatlantic.com/technology/archive/2013/05/pilots-salt-the-third-reich-kept-its-soldiers-alert-with-meth/276429/ Gifford, Bill. “The Scientific AmericanGuide to Cheating in the Olympics.” Scientific American. August 5, 2016. https://www.scientificamerican.com/article/the-scientific-american-guide-to-cheating-in-the-olympics/ Gorvett, Zaria. “The Drug Pilots Take to Stay Awake.” BBC. March 14, 2024. https://www.bbc.com/future/article/20240314-the-drug-pilots-take-to-stay-awake Grinspoon, Lester. “The speed culture : amphetamine use and abuse in America.” Harvard University Press. 1975. Accessed online: https://archive.org/details/speedcultureamph0000grin_n3i0/mode/1up Gupta, Raghav et al. “Understanding the Influence of Parkinson Disease on Adolf Hitler's Decision-Making during World War II.” World Neurosurgery. Volume 84, Issue 5. 2015. Pages 1447-1452. https://doi.org/10.1016/j.wneu.2015.06.014. Hurst, Fabienne. “The German Granddaddy of Crystal Meth.” Spiegel. Dec. 23, 2013. https://www.spiegel.de/international/germany/crystal-meth-origins-link-back-to-nazi-germany-and-world-war-ii-a-901755.html Isenberg, Madison. “Volksdrogen: The Third Reich Powered by Methamphetamine.” The Macksey Journal. University of Texas at Tyler. Volume 4, Article 21. 2023. https://scholarworks.uttyler.edu/cgi/viewcontent.cgi?article=1001&context=senior_projects Laskow, Sarah. “Brewing Bad: The All-Natural Origins of Meth.” The Atlantic. Oct. 3, 2014. https://www.theatlantic.com/technology/archive/2014/10/brewing-bad-the-all-natural-origins-of-meth/381045/ Lee, Ella. “Fact check: Cocaine in Coke? Soda once contained drug but likely much less than post claims.” USA Today. July 25, 2021. https://www.usatoday.com/story/news/factcheck/2021/07/25/fact-check-coke-once-contained-cocaine-but-likely-less-than-claimed/8008325002/ Leite, Fagner Carvalho et al. “Curine, an alkaloid isolated from Chondrodendron platyphyllum inhibits prostaglandin E2 in experimental models of inflammation and pain.” Planta medica 80,13 (2014): 1072-8. doi:10.1055/s-0034-1382997 Meyer, Ulrich. “Fritz hauschild (1908-1974) and drug research in the 'German Democratic Republic' (GDR).” Die Pharmazie 60 6 (2005): 468-72. Natale, Fabian. “Pervitin: how drugs transformed warfare in 1939-45.” Security Distillery. May 6, 2020. https://thesecuritydistillery.org/all-articles/pervitin-how-drugs-transformed-warfare-in-1939-45 Ohler, Norman. “Blitzed: Drugs in the Third Reich.” Houghton Mifflin Harcourt. 2017. Rasmussen, Nicolas. “Medical Science and the Military: The Allies’ Use of Amphetamine during World War II.” The Journal of Interdisciplinary History, vol. 42, no. 2, 2011, pp. 205–33. JSTOR, http://www.jstor.org/stable/41291190 “Reich Minister of Health Dr. Leonardo Conti Speaks with Hitler’s Personal Physician, Dr. Karl Brandt (August 1, 1942).” German History in Documents and Images. https://germanhistorydocs.org/en/nazi-germany-1933-1945/reich-minister-of-health-dr-leonardo-conti-speaks-with-hitler-s-personal-physician-dr-karl-brandt-august-1-1942 Schwarcz, Joe. “The Right Chemistry: Once a weapon, methamphetamine is now a target.” Oct. 1, 2021. https://montrealgazette.com/opinion/columnists/the-right-chemistry-once-a-weapon-methamphetamine-is-now-a-target Snelders, Stephen and Toine Pieters. “Speed in the Third Reich: Metamphetamine (Pervitin) Use and a Drug History From Below.” Social History of Medicine. Volume 24, Issue 3. December 2011. Pages 686–699. https://doi.org/10.1093/shm/hkq101 “Stimulant Pervitin.” Deutschland Museum. https://www.deutschlandmuseum.de/en/collection/stimulant-pervitin/ Tinsley, Grant. “Ephedra (Ma Huang): Weight Loss, Dangers, and Legal Status.” Helthline. March 14, 2019. https://www.healthline.com/nutrition/ephedra-sinica See omnystudio.com/listener for privacy information.

Host John Beckner is joined by Ed Cohen, founder and COO of PharmTeam Associates, and Megan Smith, PharmD, director of the UAMS Community-Based Residency Program and associate professor at the University of Arkansas for Medical Sciences, to explore how community pharmacy has evolved, and why no two community pharmacies are the same.

Tony: -Carbonation Station: Lando Reviews Lando!   -More Autonomous Lies: https://www.techspot.com/news/111233-waymo-admits-autopilot-often-guys-philippines.html   -Trump Phone situation continues to amaze: https://www.engadget.com/mobile/smartphones/trump-mobiles-t1-phone-is-apparently-still-coming-but-itll-be-uglier-and-more-expensive-190626835.html   -Another possibly awesome BT option: https://www.audioreviews.org/noble-announces-sceptre/   -The FDA continues to circle the drain: https://arstechnica.com/health/2026/02/fda-refuses-to-review-modernas-mrna-flu-vaccine/   -Snapmaker U1 has arrived!   Jarron:  -Tesla is canceling Model S and Model X https://www.cnn.com/2026/01/28/business/tesla-q4-2025-earnings   -Sodium Ion batteries incoming: The World's First Sodium-Ion Battery in Commercial EVs - Great at Low Temperatures   -Biohacking to get ahead at the Olympics: https://arstechnica.com/health/2026/02/penisgate-erupts-at-olympics-scandal-exposes-risks-of-bulking-your-budge/   -Rivian R2 shown off https://www.theverge.com/transportation/876441/the-early-reviews-of-the-rivian-r2-are-starting-to-roll-in   Owen: -Discord cracking down https://www.theverge.com/tech/875309/discord-age-verification-global-roll-out -Discord Clarification: https://discord.com/press-releases/discord-launches-teen-by-default-settings-globally Lando:   -AI Ads https://techcrunch.com/2026/02/09/chatgpt-rolls-out-ads/   -Fart Tech https://gizmodo.com/how-many-times-do-you-fart-a-day-smart-underwear-says-its-way-more-than-you-think-2000719805

Dr. Monty Pal and Dr. Atul Batra discuss the PLANeT study from India, which evaluated low-dose pembrolizumab in addition to neoadjuvant chemotherapy for triple-negative breast cancer, and its place among a growing body of international research on improving efficacy while reducing costs and toxicity with lower doses of immunotherapy. TRANSCRIPT Dr. Monty Pal: Hello and welcome to the ASCO Daily News Podcast. I'm your host, Dr. Monty Pal. I'm a medical oncologist, professor, and vice chair of academic affairs at the City of Hope Comprehensive Cancer Center, Los Angeles. My guest today, I think, is going to be a really riveting one. It's Dr. Atul Batra, who is an additional professor of medical oncology at the All India Institute of Medical Sciences, or AIIMS, in New Delhi. And he's also the senior author of the PLANeT study. It's a very compelling study that evaluated low-dose pembrolizumab in addition to neoadjuvant chemotherapy for triple-negative breast cancer. And it's really a big part of a growing body of research that's showing balanced efficacy when we use lower doses of immunotherapy instead of standard doses to reduce cost, as well as potentially toxicity. I think this has huge implications for our global audience, and I'm so thrilled to have you on the podcast today, Dr. Atul Batra, welcome. Dr. Atul Batra: Thank you, Dr. Pal. Dr. Monty Pal: And we'll just take it with first names from here since we're both friends. I have to give the audience some context. Atul, I had the great honor of visiting AIIMS New Delhi. For those that don't know, this is really, you know, the Harvard Medical School of India. It's the most competitive institution for medical training. And on the back end of that, there's also incredible resources when it comes to clinical trials and infrastructure. I just wanted to have you give the audience sort of a scope of the types of trials that you've been able to do at AIIMS New Delhi. Dr. Atul Batra: Thank you, Monty. So, I work at the All India Institute of Medical Sciences, and we had the honor and pleasure of having Monty here this month. And people are still in awe of his lectures that he delivered there. Coming back to our institute, so it's kind of a medical college. It's one of the oldest ones, it was built in 1956. We are lucky enough that we get the best of the residents and fellows because they have to go through an exam, a competitive exam, and mostly it's them who come to us and we're able to do some good work out here. Regarding the trials that we have conducted, we do conduct some investigator-initiated studies, and we try to answer the questions where we can help our own patients. Like, for example, this PLANeT study. Every other patient in the clinic was almost not able to afford Keytruda at the full dose, pembrolizumab, and we had a lot of evidence creeping in that a lower dose might be helpful. And that's how we planned this study. Before that, there are certain cancers that are peculiar to India, like gallbladder cancer, head and neck cancers. These are much more common in India as compared to the U.S., and there are some good studies that have been conducted from our own institute by our senior colleagues which have been presented at ASCO and published in the JCO. We also did the capecitabine hand-foot syndrome study that was known as the D-ToRCH study: 1% diclofenac gel that became the standard of care to prevent hand-foot syndrome.  So, that's kind of a brief overview of investigator-initiated studies. India is slowly and steadily becoming a partner of the global registration trials. And it's more recently, the last five years or so, we have seen that the number of phase 2 and phase 3 trials are increasing and we are able to offer now these trials as well to our patients. Dr. Monty Pal: That was a terrific overview. I just want to highlight for the audience, as we go through some of your discussions today around specific trials, the speed at which this can be done. Just for context, for me to accrue a clinical trial of 30 patients – I think many people have probably come across some of the work that I've done in the microbiome space – at a single institution, 30 patients, right, takes me about a year and a half, two years. We're going to go through some trials today where Dr. Batra and his team have actually, in fact, accrued close to 200 patients over a span of just a year, which is just remarkable by, I would say, any American standard. So, I see a real need for partnership and Atul, I'll kind of get back to that at the end. But without further ado, the focus of this podcast today, I think, is really this terrific presentation you gave in an oral session at ESMO and subsequently published in Annals of Oncology related to the PLANeT study. Would you give the listeners some context around what the study entailed and population and so forth? Dr. Atul Batra: So, we know the KEYNOTE-522 became the standard of care for triple-negative breast cancer, where Keytruda, when added at 200 mg, the standard dose every three weeks with neoadjuvant, increases the pCR from around 51% to 64% by a magnitude of around 13%. However, in India and other low-middle income countries, less than 5% of the patients actually have access to this dose of pembrolizumab. So, our standard of care was actually just chemotherapy till now. And this kind of led us to design this trial. There are data that come from previous trials conducted in India, from the Tata Memorial, done in head and neck space, some other studies done in Hodgkin's lymphoma, that a much lower dose, probably around one-tenth of the dose, works well in these cancers. So, that's where we designed the PLANeT study, where we gave the standard neoadjuvant chemotherapy in the control arm, and in the experimental arm we added 50 mg of pembrolizumab. This was given every six weeks for three doses. So, that's a total of 150 mg over the neoadjuvant period as compared to 1,600 mg that was given in the KEYNOTE-522 study. So, this was almost one-tenth of the study. Dr. Monty Pal: So, a tenth of the dose, which is just remarkable. I mean, that's just such an interesting concept. Dr. Atul Batra: And the results, when we – the primary outcome, this was a phase 2 study. We just wanted to see, is there a signal of activity? And to even our surprise, when we looked at the pathological complete response rates, in the control arm this was 40.5%, and in the experimental arm this was 53.8%. So, a difference came to around 13.3%; it was numerically, I mean, so much similar to what KEYNOTE-522 had with just these many doses. So, this was around 160 patients randomized over one year. We could randomize them in one year because of the load that we see. And the primary endpoint was met, and we could see that the path complete response did show a remarkable increase. We are still following these patients to see whether there is a difference in event-free survival at a longer follow-up. Until now, it's a small follow-up, so the number of events absolute, are different: four events in the experimental arm and 11 events in the control arm. So, we are seeing some signal even in this much short follow-up period as well. But we need to see more of what happens in the longer term. Dr. Monty Pal: That's so impressive. I wonder, with this lower dose, do you attenuate toxicity at all as far as you can gather? Dr. Atul Batra: So, although we shouldn't be doing kind of cross-trial comparisons, but if you look at thyroid dysfunction, we saw that around 10% of our patients had this thyroid dysfunction. This was compared to 15% in the KEYNOTE-522, that was a larger sample size though. But we're seeing that all the toxicities are somewhat less as compared to those in the standard dose. So, the exposure is less, but I mean, I can't really commit definitely on this. For this we would need much more data to say this with more confidence. Dr. Monty Pal: Yeah. I'm going to ask you a really tough question to follow up, and this is probably something that's on everyone's mind after reading a study like this. Is this something that is disease-specific that needs to be replicated across other histologies? The reason I ask this is, you know, you think about paradigms like, for instance, in the States we're toying between intravenous versus subcutaneous delivery of checkpoint inhibitors, and we have studies focused in specific histologies that might justify use across all histologies. With this particular phenomenon, do you think we need to do dedicated studies in renal cell or in colon cancer and other places where, you know, in selected settings we might use checkpoint inhibitors and then decide whether or not there's this dose equivalence, if you will? Dr. Atul Batra: That's a real tough one, though. But I'm happy to share that there are several ongoing studies within India currently. At our institute, my colleagues are leading studies in lung cancer space, cervical cancer. There was already a publication from Tata Memorial Hospital in head and neck cancers and we see that the signal has been consistent throughout. Regarding renal cancer, there was one study that was presented for sure at ASCO from CMC Vellore, that's again a center in South India. That was in RCC at a much lower dose. And for patients who cannot take the full dose, we actually are offering lower dose nivolumab in such patients and we are seeing responses. I mean, we haven't done those randomized trials again because the numbers are much lower in kidney cancers, we know. We could do this trial in triple-negative ones because we had support and we had numbers to conduct this trial. But I'm sure this should be a class effect. I mean, when we can get tumor-agnostic approvals, then some real-world data has come up in almost all tumors, we have seen that consistent effect across tumors. And as we speak of today, I'm also delighted to share that in India, yesterday, we had the first biosimilar of nivolumab and that's now available at a much, much lower price than the original patent product. There was a long ongoing lawsuit that was there, that's over now, and from yesterday onwards, I'm so happy to share here that we would have the first biosimilar of nivolumab that's available. That's going to bring the cost to almost like one-tenth already. Dr. Monty Pal: Wow. That's huge.  I'm going to be very selfish here for a second and focus on a study that is in the renal cell space that your group has done. You know, when it came out, I was really sort of intrigued by this study as well and it reflects sort of a different capability, I think, of AIIMS New Delhi, and that's in the, what I'm going to call, biomarker space. This, for the audience, was a prospective effort to characterize germline variants in patients with advanced kidney cancer. And it's something that we talk about a lot in the kidney cancer literature, whether or not we're missing a lot of these so-called hereditary patterns of RCC. Can you tell us a little bit about that study too? Dr. Atul Batra: Yeah, so that was led by one of our fellows, Chitrakshi Nagpal, and she's just completed her fellowship. And two years back we published that. So, that was done in almost 160 consecutive patients that we recruited over the span of just one year and we saw, apart from the common known mutations in RCC, that was around 5% or so, but a lot of other mutations were also seen that we don't generally see in kidney cancers and we see in other cancers like BRCA1, BRCA2 and others. We are still, I mean, doing those analyses to see whether we get more things out of there in the somatic: is there a loss of heterozygosity or was it just present and in there? Dr. Monty Pal: I thought it was a terrific study and again, I was just so blown away at the pace. I mean, as I look at 140 patients accrued over a span of one year, this is something that would take us perhaps three times as long at City of Hope, and that's with a very sort of, what I consider to be large and dedicated kidney cancer program. So, it really underscores, I think, the need for collaboration. And ever since I came back from my visit to you at AIIMS Delhi, I think I've just been sort of transformed in the sense of trying to think of better ways for us to collaborate. One tangible thing that I'm going to get cracking on is seeing whether or not perhaps we can form some partnerships through SWOG or what we call the NCTN, the National Clinical Trials Network here within the U.S. Talk to me about collaboration. I mean, you've been really terrific at this. How do you sort of envision collaboration enhancing the global landscape of oncology? Dr. Atul Batra: That's really amazing, Monty. That's what we need. We have the infrastructure, we have the manpower, we have patients. I mean, these are all high-volume centers. Unfortunately, we are a little less in numbers, so we are more clinically occupied as well. So, sometimes it's kind of tougher, but again, when it comes to helping out the patients, global collaboration, we need to kind of take you guys along with us and have our patients finish trials earlier. This is a win-win situation for patients, one, because they also get exposure or an option to participate in the clinical trials, and second, we can answer all these scientific questions that we have at a much faster pace. All those things can be done within a much shorter span of time for sure. We are so happy to hear that, and with open hands we are ready to collaborate for all these efforts. Dr. Monty Pal: That's awesome. You know, I came back thinking, gosh, this would be so ideal for some of these rare subtypes of kidney cancer. Prospective clinical trials that I'm running in that space where really we're threatened with closure all the time. And if we just sort of extended a hand to, you know, our partners in India and other countries, you know, I'm sure we could get this research done in a meaningful way and that's got to be a win for patients. Atul, I had such a terrific time chatting with you today. I'm looking forward to seeing lots more productivity from your group there. By the way, for our viewership here, take a look and see what AIIMS New Delhi is doing under the leadership of Dr. Batra and others. It is just a real powerhouse and I think that after doing so, you'll be enticed to collaborate as well.  I'm hoping this is the first of many times that we have you on the podcast. Thank you so much for joining. Dr. Atul Batra: Thank you so much for having me here, Monty. It was a pleasure as always speaking to you. And thank you again. Dr. Monty Pal: You got it.  Well, and thanks to our listeners. I encourage you to check out Dr. Batra's paper. We'll actually have a link to the study in the transcript of this episode.  Finally, if you value the insights that you heard today on the ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. More on today's speakers:     Dr. Monty Pal   @montypal Dr. Atul Batra @batraatulonc Follow ASCO on social media:          ASCO on X    ASCO on Bluesky         ASCO on Facebook          ASCO on LinkedIn          Disclosures:       Dr. Monty Pal:      Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview     Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical     Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis     Dr. Atul Batra: Stock and Other Ownership Interests: Zydus Pharmaceuticals, Glenmark, Caplin Point Laboratories, Laurus Research Funding: AstraZeneca, Astellas Pharma, Alkem Laboratories

Send us a textFebruary is National Heart Month, and in the month of hearts, we're revisiting one of the most important conversations from the Ageless Glamour Girls™ Podcast archives.Broken Heart Syndrome can mimic the symptoms of a heart attack - and it can occur after sudden, intense emotional or physical stress. Research shows cases are increasing, particularly among middle-aged and older women. This episode originally aired during our debut season in March 2022, but its message feels even more urgent today. We're joined by Dr. Susan Cheng, senior author of a major study on the condition and a leading cardiologist at the Smidt Heart Institute at Cedars-Sinai. Dr. Cheng breaks down:What Broken Heart Syndrome is - and what it isn'tWhy women are disproportionately affectedThe powerful role stress plays in heart healthAnd, most importantly, why this condition is treatableIf you've ever felt the physical weight of emotional stress, this conversation matters. And here's to Healthy Aging and Joyful Living, Luvvies!**********************GUEST BIO: Susan Cheng, MD, MMSc, MPH is the Erika J. Glazer Chair in Cardiovascular Health and Population Science, Director of the Institute for Research on Healthy Aging, and Director of Population Health Sciences at the Smidt Heart Institute at Cedars-Sinai. She also serves as Professor and Vice Chair of Research Affairs in the Department of Cardiology. Dr. Cheng is a cardiologist, echocardiographer, and clinician-scientist who leads nationally recognized research programs focused on the drivers of cardiovascular aging in women and men. She received her bachelor's degree from Harvard College, her medical degree from McMaster University, a Master of Medical Science from MIT, and a Master of Public Health from Harvard.She completed internal medicine training at The Johns Hopkins Hospital and cardiology training at Brigham and Women's Hospital and Harvard Medical School, where she later served as cardiology faculty and Associate Director of the Cardiovascular Imaging Core Laboratory. Dr. Cheng is also Co-Director of the Framingham Heart Study Echocardiography Laboratory and Co-Director of the international Bioactive LipidsNet Consortium. She has served on editorial boards of major cardiovascular and imaging journals and on leadership committees for the American Heart Association and the American College of Cardiology. Dr. Cheng has chaired and contributed to multiple American Heart Association scientific statements on research methods, heart disease statistics, and cardiovascular care of older adults. She has authored more than 4Support the show https://buymeacoffee.com/agelessglamourgirls www.linkedin.com/in/marqueetacurtishaynes www.agelessglamourgirls.com https://www.shopltk.com/explore/AgelessGlamourGirls https://www.youtube.com/@agelessglamourgirls Instagram @agelessglamourgirls Facebook: https://www.facebook.com/agelessglamourgirls Private (AGG) FB Group: The Ageless Café: https://www.facebook.com/groups/theagelesscafe TikTok: @agelessglamourgirls Podcast Producers: Ageless Glamour Girls and Purple Tulip Media, LLC

Matthew David and Randy Olson have a preliminary discussion of David H Freedman's 2010 Atlantic article, "Lies, Damned Lies, and Medical Science."  We work on our 3 questions each that we'll be asking David to start the discussion.  Please join us on Wednesday, Feb 11th, 10:00 am PST, RSVP here:  https://www.eventbrite.com/e/adventures-in-medical-misinformation-two-cases-of-misperception-tickets-1980404588435?aff=oddtdtcreator   Randy Olson https://x.com/ABTagenda Randy's Blog: https://abtagenda.substack.com/ Learn more about the ABT Framework Course: http://abtnarrative.com/

What happens when a health system stops trying to recruit its way out of a workforce challenge, and instead redesigns the pipeline itself? In this episode of Bright Spots in Healthcare, Eric Glazer sits down with Dr. Lindsay Mazotti, Chief Medical Officer of Medical Science and Education at Sutter Health, for a candid, system-level conversation about rethinking how physicians are trained, supported, and developed for the future of care. Rather than focusing on workforce shortages as a policy or awareness problem, this conversation explores what happens after the reality is already clear—when leaders choose to redesign foundational systems instead of managing around constraints. Dr. Mazotti shares how Sutter is treating graduate medical education as strategic infrastructure, not an academic side function, and what it takes to build a physician pipeline that can scale, adapt, and endure. Using examples from rural training pathways, academic partnerships, research translation, and digital transformation, the discussion surfaces how education becomes the load-bearing structure that allows health systems to absorb change without breaking. This episode is designed for health system leaders who are no longer asking whether change is needed, but are grappling with how to build systems that can carry what's coming next. In this episode, we cover: Why physician shortages can't be solved through recruiting alone How Sutter is redesigning the physician pipeline end to end What changes when graduate medical education is treated as core infrastructure How training clinicians for place shapes rural and underserved care delivery Why education is the missing link between research, digital innovation, and day-to-day care Where clinician training determines adoption—or abandonment—of new technologies The leadership tradeoffs that come with moving from individual patient care to system-level impact What leaders must unlearn when building durable, long-term capability About Dr. Lindsay Mazotti: Dr. Lindsay Mazotti leads system-wide initiatives at Sutter Health that advance medical education, research, and innovation in support of the organization's mission to deliver exceptional, patient-centered care to more than 3 million patients across 22 counties in Northern California. In her role, she focuses on strategically integrating medical education into the health system's infrastructure to align with long-term priorities, including Sutter's Destination 2030 initiative. Dr. Mazotti oversees undergraduate and graduate medical education across the system—spanning clinical rotations, scholarships, residency and fellowship programs, and academic partnerships—while working closely with aligned medical groups representing more than 14,000 physicians to develop and support physician educators. Her work centers on building innovative training pathways that address physician workforce needs, align with evolving care delivery models, and strengthen long-term system capability, with the goal of quadrupling Sutter's GME footprint by 2030 to become the largest community-based GME program in California. Learn more about Dr. Mazotti - https://www.linkedin.com/in/lindsay-mazotti Partner with Bright Spots Ventures: If you are interested in speaking with the Bright Spots Ventures team to brainstorm how we can help you grow your business via content and relationships, email hkrish@brightspotsventures.com. About Bright Spots Ventures: Bright Spots Ventures is a healthcare strategy and engagement company that creates content, communities, and connections to accelerate innovation. We help healthcare leaders discover what's working, and how to scale it. By bringing together health plan, hospital, and solution leaders, we facilitate the exchange of ideas that lead to measurable impact. Through our podcast, executive councils, private events, and go-to-market strategy work, we surface and amplify the "bright spots" in healthcare—proven innovations others can learn from and replicate. At our core, we exist to create trusted relationships that make real progress possible. Visit our website at www.brightspotsinhealthcare.com. Visit our website:  www.brightspotsinhealthcare.com. Follow Bright Spots in Healthcare: https://www.linkedin.com/company/shared-purpose-connect

Is the biopsy needle more dangerous than the cancer itself? In this episode, Dr. Geo sits down with Dr. Mark Emberton, Dean of Medical Sciences at UCL and a global leader in urologic oncology. We dive deep into the "See and Treat" revolution—a massive shift in prostate cancer care that moves away from "blind" invasive biopsies toward precision imaging like MRI and PSMA PET scans.Dr. Emberton explains why many prostate cancers found through traditional methods are "biological non-events" that never needed treatment, and how younger men (ages 40-50) can better navigate their diagnosis. We also discuss the future of focal therapy, the role of AI in radiology, and the groundbreaking "Transform" study that aims to change prostate screening forever.WHAT YOU'LL LEARN IN THIS EPISODE:✅ Why a normal MRI (PI-RADS 1-2) might mean you can skip the biopsy entirely.✅ The difference between "visible" tumors on imaging vs. microscopic disease.✅ How PSA density acts as the crucial "tie-breaker" for indeterminate results.✅ The future of "See and Treat": Targeting lesions while avoiding surgery side effects.✅ Why tumor location (Anterior vs. Posterior) changes your treatment options.✅ How AI and new magnets are making MRI screening cheaper and faster.

With Piotr Futyma, St. Joseph's Heart Rhythm Center, Rzeszow - Poland, Stefan Simovic, Faculty of Medical Sciences, University of Kragujevac, Kragujevac - Serbia and Anthony Li, St George's University of London, London - UK. In this episode of EHRA Cardio Talk, we welcome Piotr Futyma, a leading expert in bipolar ablation and an active member of the EHRA Scientific Initiatives Committee. Together with hosts Stefan Simovic and Anthony Li, he explores the evolving role of bipolar ablation, discusses current challenges and future opportunities, and shares practical insights from clinical experience.

Is the biopsy needle more dangerous than the cancer itself? In this episode, Dr. Geo sits down with Dr. Mark Emberton, Dean of Medical Sciences at UCL and a global leader in urologic oncology. We dive deep into the "See and Treat" revolution—a massive shift in prostate cancer care that moves away from "blind" invasive biopsies toward precision imaging like MRI and PSMA PET scans.Dr. Emberton explains why many prostate cancers found through traditional methods are "biological non-events" that never needed treatment, and how younger men (ages 40-50) can better navigate their diagnosis. We also discuss the future of focal therapy, the role of AI in radiology, and the groundbreaking "Transform" study that aims to change prostate screening forever.WHAT YOU'LL LEARN IN THIS EPISODE:✅ Why a normal MRI (PI-RADS 1-2) might mean you can skip the biopsy entirely.✅ The difference between "visible" tumors on imaging vs. microscopic disease.✅ How PSA density acts as the crucial "tie-breaker" for indeterminate results.✅ The future of "See and Treat": Targeting lesions while avoiding surgery side effects.✅ Why tumor location (Anterior vs. Posterior) changes your treatment options.✅ How AI and new magnets are making MRI screening cheaper and faster.

Grieving is a uniquely human emotion – or is it? Is the apparent attachment of elephants or orcas to the bodies of dead relatives a sign of grief, or simply an instinctive behaviour without emotional implications? Why do some people seem able to handle grief so much better than others? And how close are we to finding a pharmaceutical ‘cure' for grief…and if we find it, should we use it?This lecture was recorded by Professor Robin May on the 21st of January 2026 at Barnard's Inn Hall, LondonProfessor of Infectious Disease at the University of Birmingham, and (interim) Chief Scientist at the UK Health Security Agency, Robin May was appointed Gresham Professor of Physic in May 2022. Between July 2020 and September 2025 he served as Chief Scientific Adviser at the Food Standards Agency (FSA).Professor May's early training was in Plant Sciences at the University of Oxford, followed by a PhD on mammalian cell biology at University College London and the University of Birmingham. After postdoctoral research on gene silencing at the Hubrecht Laboratory, The Netherlands, he returned to the UK in 2005 to establish a research program on human infectious diseases. He was Director of the Institute of Microbiology and Infection at the University of Birmingham from 2017-2020. Professor May continues his work on Infectious Disease at the University of Birmingham. A Fellow of the Academy of Medical Sciences, Wolfson Royal Society Research Merit Fellow and Fellow of the American Academy of Microbiology, Professor May specialises in research into human infectious diseases, with a particular focus on how pathogens survive and replicate within host organisms.As the FSA's Chief Scientific Adviser, Professor May provides expert scientific advice to the UK government and plays a critical role in helping to understand how scientific developments will shape the work of the FSA, as well as the strategic implications of any possible changes.The transcript of the lecture is available from the Gresham College website: https://www.gresham.ac.uk/watch-now/why-grieveGresham College has offered free public lectures for over 400 years, thanks to the generosity of our supporters. There are currently over 2,500 lectures free to access. We believe that everyone should have the opportunity to learn from some of the greatest minds. To support Gresham College's mission, please consider making a donation: https://www.gresham.ac.uk/get-involved/support-us/make-donation/donate-today Website:  https://gresham.ac.ukX: https://x.com/GreshamCollegeFacebook: https://facebook.com/greshamcollegeInstagram: https://instagram.com/greshamcollegeBluesky: https://bsky.app/profile/greshamcollege.bsky.social TikTok: https://www.tiktok.com/@greshamcollegeSupport Us: https://www.gresham.ac.uk/get-involved/support-us/make-donation/donate-todaySupport the show

Send us a textIn episode #170 we spoke with researcher Dr. David Church about:The crucial role of muscle protein synthesis in endurance athletesThe role of essential amino acids on muscle growth and recoveryThe impact of sleep deprivation on muscle recovery and performance.Dr. David Church, the Director of the Center for Translational Research in Aging & Longevity at University of Arkansas for Medical Sciences, College of Medicine. Dr. Church obtained his bachelor's degree in exercise science and biochemistry from DePauw University where he played football and baseball. He was an athletic performance intern at Baylor University where he studied exercise and nutritional biochemistry. He obtained his PhD from the University of Central Florida with a focus on enhancing human performance through exercise and nutrition and completed his post-doctoral fellowship in stable-isotope tracer methodology under the mentorship of Drs. Robert R. Wolfe and Arny Ferrando. He has led multiple trials investigating energy restriction in healthy and clinical populations including two active trials on individuals prescribed GLP-1RA's. He has been recognized for his work with the Nutrition Research Achievement Award from the National Strength and Conditioning Society, the Vernon Young International Award for Amino Acid Research from the American Society for Nutrition, and a Fellow of the International Society of Sports Nutrition.Please note that this podcast is created strictly for educational purposes and should never be used for medical diagnosis or treatment.Follow Dr. Church:InstagramWebMentioned:Dr. Dan MooreDr. Mikkel OxfeldtSleep studies:pmc.ncbi.nlm.nih.gov/articles/PMC7785053/pmc.ncbi.nlm.nih.gov/articles/PMC6917985/Dr. Shiloah KviatkovskyDr. Keith Barr, NR episode 82, collagenWhey Protein IsolateEssential Amino AcidsDr. Heather LeidyMORE NR Save 10% on our website with code NEWPOD10 Apply to work with us, click here: https://nutritional-revolution.com/ Follow us @nutritionalrevolution Save 20% on supplements at our trusted online source: https://us.fullscript.com/welcome/kchannell Join Nutritional Revolution's The Feed Club to get $20 off with an additional $20 Feed credit drop every 90 days.: https://thefeed.com/teams/nutritional-revolution If you're interested in sponsoring Nutritional Revolution Podcast, shoot us an email at nutritionalrev@gmail.com.

Share your guest suggestions hereMail - connect@beerbiceps.comLink - https://forms.gle/aoMHY9EE3Cg3Tqdx9Check out BeerBiceps SkillHouse's YouTube 1O1 Course - https://youtube.beerbicepsskillhouse.in/youtube-101For all BeerBiceps vlog content Watch Life Of BeerBiceps - https://www.youtube.com/@LifeOfBeerBicepsBeerBiceps SkillHouse को Social Media पर Follow करे :-YouTube : https://www.youtube.com/channel/UC2-Y36TqZ5MH6N1cWpmsBRQ Instagram : https://www.instagram.com/beerbiceps_skillhouseWebsite : https://beerbicepsskillhouse.inFor any other queries EMAIL: support@beerbicepsskillhouse.comIn case of any payment-related issues, kindly write to support@tagmango.comLevel Supermind - Mind Performance App को Download करिए यहाँ से

We examined the psychology of imposter syndrome (the imposter phenomenon) and explored strategies to help overcome it to create more confident employees. In this Episode: Dr. Heather Morton, Tom Bradshaw, Lee Crowson, LindaAnn Rogers, Nic Krueger, Emi Barresi, Dr. Martha Grajdek, Rich Cruz, Cam Dunson, Dr. Amanda Shelton, Alexander Abney-King, Dr. Matt Lampe   Visit us https://www.seboc.com/ Follow us on LinkedIn: https://bit.ly/sebocLI Join an open-mic event: https://www.seboc.com/events   References: Arciniega, L. M., Servitje, A., & Woehr, D. J. (2021). Impacting the bottom line: Exploring the effect of a self‐efficacy oriented training intervention on unit‐level sales growth. Human Resource Development Quarterly, 32(4), 559–576.  https://doi-org.libauth.purdueglobal.edu/10.1002/hrdq.21433   Carey, M. & Forsyth, A. (2009). Teaching tip sheet: Self-efficacy. American Psychological Association (APA).  https://www.apa.org/pi/aids/resources/education/self-efficacy  Chrousos, G. P., & Mentis, A. F. A. (2020). Imposter syndrome threatens diversity. Science, 367(6479), 749-750.   Gallagher, M.W. (2012). Encyclopedia of Human Behavior (Second Edition). Self-efficacy. Via ScienceDirect:  https://www.sciencedirect.com/topics/psychology/self-efficacy-theory   Locke, E. A., & Latham, G. P. (2019). The development of goal setting theory: A half-century retrospective. Motivation Science, 5(2), 93–105.  https://doi-org.libauth.purdueglobal.edu/10.1037/mot0000127   Sheykhangafshe, F. B., Nouri, E., Niri, V. S., Choubtashani, M., & Farahani, H. (2024). The efficacy of Cognitive Behavioral Therapy on mental health, self-esteem and emotion regulation of medical students with imposter syndrome. Educational Research in Medical Sciences, 13(1).   Recommended scales: Eysenck Self-esteem Scale (ESES) Imposter Syndrome Scale

With Kristina Haugaa, Oslo University Hospital Rikshospitalet, Oslo - Norway, Stefan Simovic, Faculty of Medical Sciences, University of Kragujevac, Kragujevac - Serbia and Augusto Meretta, Leiden University Medical Center, Leiden - The Netherlands. During this podcast, Kristina Haugaa, Augusto Meretta and Stefan Simovic will explore how to diagnose and manage arrhythmias safely during pregnancy, balancing maternal and fetal health through multidisciplinary, evidence-based care.

Share your guest suggestions hereMail - connect@beerbiceps.comLink - https://forms.gle/aoMHY9EE3Cg3Tqdx9Check out BeerBiceps SkillHouse's YouTube 1O1 Course - https://youtube.beerbicepsskillhouse.in/youtube-101BeerBiceps SkillHouse को Social Media पर Follow करे :-YouTube : https://www.youtube.com/channel/UC2-Y36TqZ5MH6N1cWpmsBRQ Instagram : https://www.instagram.com/beerbiceps_skillhouseWebsite : https://beerbicepsskillhouse.inFor any other queries EMAIL: support@beerbicepsskillhouse.comIn case of any payment-related issues, kindly write to support@tagmango.comLevel Supermind - Mind Performance App को Download करिए यहाँ से

Laughter is an incredibly powerful and yet mysterious emotion. We laugh with delight, but also surprise. We laugh at jokes, but also at embarrassment. Why? What subconscious signal is laughter intended to display? Why do we laugh when someone tickles us and what should we make of the fact that rodents do it too? And why is it that people's sense of humour differs wildly and yet some drugs can send us all into fits of the giggles, even if there is nothing to laugh at?This lecture was recorded by Robin May on the 12th of November 2025 at Bernard's Inn Hall, LondonProfessor of Infectious Disease at the University of Birmingham, and (interim) Chief Scientist at the UK Health Security Agency, Robin May was appointed Gresham Professor of Physic in May 2022. Between July 2020 and September 2025 he served as Chief Scientific Adviser at the Food Standards Agency (FSA). Professor May's early training was in Plant Sciences at the University of Oxford, followed by a PhD on mammalian cell biology at University College London and the University of Birmingham. After postdoctoral research on gene silencing at the Hubrecht Laboratory, The Netherlands, he returned to the UK in 2005 to establish a research program on human infectious diseases. He was Director of the Institute of Microbiology and Infection at the University of Birmingham from 2017-2020. Professor May continues his work on Infectious Disease at the University of Birmingham. A Fellow of the Academy of Medical Sciences, Wolfson Royal Society Research Merit Fellow and Fellow of the American Academy of Microbiology, Professor May specialises in research into human infectious diseases, with a particular focus on how pathogens survive and replicate within host organisms.As the FSA's Chief Scientific Adviser, Professor May provides expert scientific advice to the UK government and plays a critical role in helping to understand how scientific developments will shape the work of the FSA, as well as the strategic implications of any possible changes.The transcript of the lecture is available from the Gresham College website: https://www.gresham.ac.uk/watch-now/why-laughGresham College has offered free public lectures for over 400 years, thanks to the generosity of our supporters. There are currently over 2,500 lectures free to access. We believe that everyone should have the opportunity to learn from some of the greatest minds. To support Gresham College's mission, please consider making a donation: https://www.gresham.ac.uk/get-involved/support-us/make-donation/donate-today Website:  https://gresham.ac.ukX: https://x.com/GreshamCollegeFacebook: https://facebook.com/greshamcollegeInstagram: https://instagram.com/greshamcollegeBluesky: https://bsky.app/profile/greshamcollege.bsky.social TikTok: https://www.tiktok.com/@greshamcollegeSupport Us: https://www.gresham.ac.uk/get-involved/support-us/make-donation/donate-todaySupport the show

Root-cause strategies for perimenopause, thyroid issues, and GLP-1 use—helping women achieve sustainable, muscle-preserving weight loss.----In this episode, I talk with Margaux Cousturian, PA-C, about the real reasons women struggle with stubborn weight gain—especially in their 30s, 40s, and 50s. We explore how perimenopause, thyroid health, stress, inflammation, and GLP-1 medications intersect, and why lasting results require more than calorie counting. Margo shares practical steps, smarter lab testing, and simple strategies to support muscle, metabolism, and sustainable weight loss.----Margaux Cousturian is a dedicated and experienced Physician Associate (PA-C) with a Master of Medical Science in Physician Assistant Studies from Mercer University. She completed her undergraduate studies at the University of North Georgia, earning a Bachelor of Science in Biology with Honors. Margaux brings a wealth of expertise in integrative and functional medicine to her role at Forum Health Knoxville, where she specializes in hormone therapy, autoimmunity, weight loss, and preventive health. Margaux has built a reputation for her leadership in gastrointestinal (GI) and autoimmune treatments. Margaux is also a published researcher, with her work featured in PLOS ONE, exploring treatments for bowel conditions. She has completed advanced training in functional medicine through the Applying Functional Medicine in Clinical Practice (AFMCP) program and is working toward certification with the Institute of Functional Medicine (IFM). Margaux is an advocate for patient education and is a frequent speaker at wellness events, including the Knoxville Wellness Innovation Summit and the HotWorx Stress Management Seminar. She is passionate about empowering her patients through personalized, comprehensive care that addresses both the root causes of illness and long-term wellness.----Forum HealthFind us at: Website: ⁠⁠⁠⁠⁠⁠⁠https://forumhealth.com/⁠⁠⁠⁠⁠⁠⁠Clinic Locator: ⁠⁠⁠⁠⁠⁠⁠https://forumhealth.com/clinics/⁠⁠⁠⁠⁠⁠⁠Follow us on Social: Facebook: ⁠⁠⁠⁠⁠https://www.facebook.com/forumhealthco/⁠⁠⁠⁠⁠Instagram: ⁠⁠⁠⁠⁠https://www.instagram.com/forum_health/⁠⁠⁠⁠⁠----PODCASTThank you for listening.Please subscribe and share.This podcast is produced by DrTalks.com⁠⁠⁠⁠⁠⁠https://drtalks.com/podcast-service/

On today's show,  President Barack Obama helps launch Crystal Bridges' new speaker series in Bentonville. Also, the Arkansas Crisis Center partners with the psychiatry department at the University of Arkansas for Medical Sciences to analyze two decades of call and text distress line records. 

Advertisements have recently appeared on the New York subway, offering would-be parents the chance to “genetically optimise” their future babies. So, what would this genetic modification involve, and would it be ethical to do?Joining Ciara Doherty to discuss is Professor of Medical Genetics at UCD School of Medicine and Medical Science, and Consultant Clinical Geneticist, Andrew Green.

With Andrea Sarkozy, University Hospital (UZ) Brussels, Brussels - Belgium and Stefan Simovic, Faculty of Medical Sciences, University of Kragujevac, Kragujevac - Serbia. During this podcast Andrea Sarkozy and Stefan Simovic will discuss the most impactful studies in electrophysiology published in 2025, highlighting key findings, clinical implications, and how they may influence future practice.

Ambassador Ian Hale has written Support Platform extensively about autism. He himself identifies as being on the spectrum and is an amazing advocate and voice for the autism community. He is a member of the world Academy of Medical Science, Mensa, a Trustee of Autistic Nottingham and a longtime Member of the UK Government Advisory Policy

“Welcome, welcome our wonderful audience!” Dr. Peter Breggin opened The Breggin Hour this week, talking about the effects of his stroke and about our efforts to seek rehabilitation, offering the best chance of optimizing recovery from brain damage. The indomitable Karen Kingston, who has been exposing the dangers of the mRNA vaccines for over five years, joined us. Peter spent a portion of the hour further detailing his experience of receiving treatment at the AVIV clinic, which offers a very specialized program of Hyperbaric Oxygen Treatment (HBOT). Peter made a comment at some point in the program, stating we must “muster great courage equal to our fear…” That phrase sums up for me my husband's attitude since his stroke. He is forging ahead, determined to embrace with both arms the work required to heal. During the third segment, we lost audio with Karen Kingston, so Peter and I finished up discussing artificial intelligence, and Karen's point that AI has been introduced just at a time when the human population is suffering from unprecedented amounts of neurological damage, from the mRNA vaccines as well as from other sources. She pointed out that the creators of the AI programs being used were doing the thinking—the cognitive work—for the individuals using it, which means humans are doing less independent thinking and creating increasing dependency upon outside sources. The neuropsychiatric damage done by mRNA vaccines is being clearly identified. Peter was a coauthor, along with other noted experts, of a recently published scientific paper: “Association Between COVID-19 Vaccination and Neuropsychiatric Conditions,” published in the International Journal of Innovative Research in Medical Science. The paper details over 58 profound neurological adverse effects resulting from mRNA vaccines. Dr. James Thorp spearheaded this research as lead author. The show was a mix of the deeply personal and an examination of some of the threats to humanity's future, with some sweet moments between Peter and Ginger.

Dr. Linda Duska and Dr. Kathleen Moore discuss key studies in the evolving controversy over radical upfront surgery versus neoadjuvant chemotherapy in advanced ovarian cancer. TRANSCRIPT Dr. Linda Duska: Hello, and welcome to the ASCO Daily News Podcast. I am your guest host, Dr. Linda Duska. I am a professor of obstetrics and gynecology at the University of Virginia School of Medicine.  On today's episode, we will explore the management of advanced ovarian cancer, specifically with respect to a question that has really stirred some controversy over time, going all the way back more than 20 years: Should we be doing radical upfront surgery in advanced ovarian cancer, or should we be doing neoadjuvant chemotherapy? So, there was a lot of hype about the TRUST study, also called ENGOT ov33/AGO-OVAR OP7, a Phase 3 randomized study that compares upfront surgery with neoadjuvant chemotherapy followed by interval surgery. So, I want to talk about that study today. And joining me for the discussion is Dr. Kathleen Moore, a professor also of obstetrics and gynecology at the University of Oklahoma and the deputy director of the Stephenson Cancer Center, also at the University of Oklahoma Health Sciences.  Dr. Moore, it is so great to be speaking with you today. Thanks for doing this. Dr. Kathleen Moore: Yeah, it's fun to be here. This is going to be fun. Dr. Linda Duska: FYI for our listeners, both of our full disclosures are available in the transcript of this episode.  So let's just jump right in. We already alluded to the fact that the TRUST study addresses a question we have been grappling with in our field. Here's the thing, we have four prior randomized trials on this exact same topic. So, share with me why we needed another one and what maybe was different about this one? Dr. Kathleen Moore: That is, I think, the key question. So we have to level-set kind of our history. Let's start with, why is this even a question? Like, why are we even talking about this today? When we are taking care of a patient with newly diagnosed ovarian cancer, the aim of surgery in advanced ovarian cancer ideally is to prolong a patient's likelihood of disease-free survival, or if you want to use the term "remission," you can use the term "remission." And I think we can all agree that our objective is to improve overall survival in a way that also does not compromise her quality of life through surgical complications, which can have a big effect. The standard for many decades, certainly my entire career, which is now over 20 years, has been to pursue what we call primary cytoreductive surgery, meaning you get a diagnosis and we go right to the operating room with a goal of achieving what we call "no gross residual." That is very different – in the olden days, you would say "optimal" and get down to some predefined small amount of tumor. Now, the goal is you remove everything you can see.  The alternative strategy to that is neoadjuvant chemotherapy followed by interval cytoreductive surgery, and that has been the, quote-unquote, "safer" route because you chemically cytoreduce the cancer, and so, the resulting surgery, I will tell you, is not necessarily easy at all. It can still be very radical surgeries, but they tend to be less radical, less need for bowel resections, splenectomy, radical procedures, and in a short-term look, would be considered safer from a postoperative consideration. Dr. Linda Duska: Well, and also maybe more likely to be successful, right? Because there's less disease, maybe, theoretically. Dr. Kathleen Moore: More likely to be successful in getting to no gross residual. Dr. Linda Duska: Right. Yeah, exactly. Dr. Kathleen Moore: I agree with that. And so, so if the end game, regardless of timing, is you get to no gross residual and you help a patient and there's no difference in overall survival, then it's a no-brainer. We would not be having this conversation. But there remains a question around, while it may be more likely to get to no gross residual, it may be, and I think we can all agree, a less radical, safer surgery, do you lose survival in the long term by this approach? This has become an increasing concern because of the increase in rates of use of neoadjuvant, not only in this country, but abroad. And so, you mentioned the four prior studies. We will not be able to go through them completely. Dr. Linda Duska: Let's talk about the two modern ones, the two from 2020 because neither one of them showed a difference in overall survival, which I think we can agree is, at the end of the day, yes, PFS would be great, but OS is what we're looking for. Dr. Kathleen Moore: OS is definitely what we're looking for. I do think a marked improvement in PFS, like a real prolongation in disease-free survival, for me would be also enough. A modest improvement does not really cut it, but if you are really, really prolonging PFS, you should see that-  Dr. Linda Duska: -manifest in OS. Dr. Kathleen Moore: Yeah, yeah. Okay. So let's talk about the two modern ones. The older ones are EORTC and CHORUS, which I think we've talked about. The two more modern ones are SCORPION and JCOG0602. So, SCORPION was interesting. SCORPION was a very small study, though. So one could say it's underpowered. 170 patients. And they looked at only patients that were incredibly high risk. So, they had to have a Fagotti score, I believe, of over 9, but they were not looking at just low volume disease. Like, those patients were not enrolled in SCORPION. It was patients where you really were questioning, "Should I go to the OR or should I do neoadjuvant? Like, what's the better thing?" It is easy when it's low volume. You're like, "We're going." These were the patients who were like, "Hm, you know, what should I do?" High volume. Patients were young, about 55. The criticism of the older studies, there are many criticisms, but one of them is that, the criticism that is lobbied is that they did not really try. Whatever surgery you got, they did not really try with median operative times of 180 minutes for primary cytoreduction, 120 for neoadjuvant. Like, you and I both know, if you're in a big primary debulking, you're there all day. It's 6 hours. Dr. Linda Duska: Right, and there was no quality control for those studies, either. Dr. Kathleen Moore: No quality control. So, SCORPION, they went 451-minute median for surgery. Like, they really went for it versus four hours and then 253 for the interval, 4 hours. They really went for it on both arms. Complete gross resection was achieved in 50% of the primary cytoreduced. So even though they went for it with these very long surgeries, they only got to the goal half the time. It was almost 80% in the interval group. So they were more successful there. And there was absolutely no difference in PFS or OS. They were right about 15 months PFS, right about 40 months OS.  JCOG0602, of course, done in Japan, a big study, 300 patients, a little bit older population. Surprisingly more stage IV disease in this study than were in SCORPION. SCORPION did not have a lot of stage IV, despite being very bulky tumors. So a third of patients were stage IV. They also had relatively shorter operative times, I would say, 240 minutes for primary, 302 for interval. So still kind of short. Complete gross resection was not achieved very often. 30% of primary cytoreduction. That is not acceptable. Dr. Linda Duska: Well, so let's talk about TRUST. What was different about TRUST? Why was this an important study for us to see? Dr. Kathleen Moore: So the criticism of all of these, and I am not trying to throw shade at anyone, but the criticism of all of these is if you are putting surgery to the test, you are putting the surgeon to the test. And you are assuming that all surgeons are trained equally and are willing to do what it takes to get someone to no gross residual. Dr. Linda Duska: And are in a center that can support the post-op care for those patients. Dr. Kathleen Moore: Which can be ICU care, prolonged time. Absolutely. So when you just open these broadly, you're assuming everyone has the surgical skills and is comfortable doing that and has backup. Everybody has an ICU. Everyone has a blood bank, and you are willing to do that. And that assumption could be wrong. And so what TRUST said is, "Okay, we are only going to open this at centers that have shown they can achieve a certain level of primary cytoreduction to no gross residual disease." And so there was quality criteria. It was based on – it was mostly a European study – so ESGO criteria were used to only allow certified centers to participate. They had to have a surgical volume of over 36 cytoreductive surgeries per year. So you could not be a low volume surgeon. Your complete resection rates that were reported had to be greater than 50% in the upfront setting. I told you on the JCOG, it was 30%. Dr. Linda Duska: Right. So these were the best of the best. This was the best possible surgical situation you could put these patients in, right? Dr. Kathleen Moore: Absolutely. And you support all the things so you could mitigate postoperative complications as well. Dr. Linda Duska: So we are asking the question now again in the ideal situation, right? Dr. Kathleen Moore: Right. Dr. Linda Duska: Which, we can talk about, may or may not be generalizable to real life, but that's a separate issue because we certainly don't have those conditions everywhere where people get cared for with ovarian cancer. But how would you interpret the results of this study? Did it show us anything different? Dr. Kathleen Moore: I am going to say how we should interpret it and then what I am thinking about. It is a negative study. It was designed to show improvement in overall survival in these ideal settings in patients with FIGO stage IIIB and C, they excluded A, these low volume tumors that should absolutely be getting surgery. So FIGO stage IIIB and C and IVA and B that were fit enough to undergo radical surgery randomized to primary cytoreduction or neoadjuvant with interval, and were all given the correct chemo. Dr. Linda Duska: And they were allowed bevacizumab and PARP, also. They could have bevacizumab and PARP. Dr. Kathleen Moore: They were allowed bevacizumab and PARP. Not many of them got PARP, but it was distributed equally, so that would not be a confounder. And so that was important. Overall survival is the endpoint. It was a big study. You know, it was almost 600 patients. So appropriately powered. So let's look at what they reported. When they looked at the patients who were enrolled, this is a large study, almost 600 patients, 345 in the primary cytoreductive arm and 343 in the neoadjuvant arm. Complete resection in these patients was 70% in the primary cytoreductive arm and 85% in the neoadjuvant arm. So in both arms, it was very high. So your selection of site and surgeon worked. You got people to their optimal outcome. So that is very different than any other study that has been reported to date. But what we saw when we looked at overall survival was no statistical difference. The median was, and I know we do not like to talk about medians, but the median in the primary cytoreductive arm was 54 months versus 48 months in the neoadjuvant arm with a hazard ratio of 0.89 and, of course, the confidence interval crossed one. So this is not statistically significant. And that was the primary endpoint. Dr. Linda Duska: I know you are getting to this. They did look at PFS, and that was statistically significant, but to your point about what are we looking for for a reasonable PFS difference? It was about two months difference. When I think about this study, and I know you are coming to this, what I thought was most interesting about this trial, besides the fact that the OS, the primary endpoint was negative, was the subgroup analyses that they did. And, of course, these are hypothesis-generating only. But if you look at, for example, specifically only the stage III group, that group did seem to potentially, again, hypothesis generating, but they did seem to benefit from upfront surgery.  And then one other thing that I want to touch on before we run out of time is, do we think it matters if the patient is BRCA germline positive? Do we think it matters if there is something in particular about that patient from a biomarker standpoint that is different? I am hopeful that more data will be coming out of this study that will help inform this. Of course, unpowered, hypothesis-generating only, but it's just really interesting. What do you think of their subset analysis? Dr. Kathleen Moore: Yeah, I think the subsets are what we are going to be talking about, but we have to emphasize that this was a negative trial as designed. Dr. Linda Duska: Absolutely. Yes. Dr. Kathleen Moore: So we cannot be apologists and be like, "But this or that." It was a negative trial as designed. Now, I am a human and a clinician, and I want what is best for my patients. So I am going to, like, go down the path of subset analyses. So if you look at the stage III tumors that got complete cytoreduction, which was 70% of the cases, your PFS was almost 28 months versus 21.8 months. Dr. Linda Duska: Yes, it becomes more significant. Dr. Kathleen Moore: Yeah, that hazard ratio is 0.69. Again, it is a subset. So even though the P value here is statistically significant, it actually should not have a P value because it is an exploratory analysis. So we have to be very careful. But the hazard ratio is 0.69. So the hypothesis is in this setting, if you're stage III and you go for it and you get someone to no gross residual versus an interval cytoreduction, you could potentially have a 31% reduction in the rate of progression for that patient who got primary cytoreduction. And you see a similar trend in the stage III patients, if you look at overall survival, although the post-progression survival is so long, it's a little bit narrow of a margin.  But I do think there are some nuggets here that, one of our colleagues who is really one of the experts in surgical studies, Dr. Mario Leitao, posted this on X, and I think it really resonated after this because we were all saying, "But what about the subsets?" He is like, "It's a negative study." But at the end of the day, you are going to sit with your patient. The patient should be seen by a GYN oncologist or surgical oncologist with specialty in cytoreduction and a medical oncologist, you know, if that person does not give chemo, and the decision should be made about what to do for that individual patient in that setting. Dr. Linda Duska: Agreed. And along those lines, if you look carefully at their data, the patients who had an upfront cytoreduction had almost twice the risk of having a stoma than the patients who had an interval cytoreduction. And they also had a higher risk of needing to have a bowel resection. The numbers were small, but still, when you look at the surgical complications, as you've already said, they're higher in the upfront group than they are in the interval group. That needs to be taken into account as well when counseling a patient, right? When you have a patient in front of you who says to you, "Dr. Moore, you can take out whatever you want, but whatever you do, don't make me a bag." As long as the patient understands what that means and what they're asking us to do, I think that we need to think about that. Dr. Kathleen Moore: I think that is a great point. And I have definitely seen in our practice, patients who say, "I absolutely would not want an ostomy. It's a nonstarter for me." And we do make different decisions. And you have to just say, "That's the decision we've made," and you kind of move on, and you can't look back and say, "Well, I wish I would have, could have, should have done something else." That is what the patient wants. Ultimately, that patient, her family, autonomous beings, they need to be fully counseled, and you need to counsel that patient as to the site that you are in, her volume of disease, and what you think you can achieve. In my opinion, a patient with stage III cancer who you have the site and the capabilities to get to no gross residual should go to the OR first. That is what I believe. I do not anymore think that for stage IV. I think that this is pretty convincing to me that that is probably a harmful thing. However, I want you to react to this. I think I am going to be a little unpopular in saying this, but for me, one of the biggest take-homes from TRUST was that whether or not, and we can talk about the subsets and the stage III looked better, and I think it did, but both groups did really well. Like, really well. And these were patients with large volume disease. This was not cherry-picked small volume stage IIIs that you could have done an optimal just by doing a hysterectomy. You know, these were patients that needed radical surgery. And both did well. And so what it speaks to me is that anytime you are going to operate on someone with ovary, whether it be frontline, whether it be a primary or interval, you need a high-volume surgeon. That is what I think this means to me. Like, I would want high volume surgeon at a center that could do these surgeries, getting that patient, my family member, me, to no gross residual. That is important. And you and I are both in training centers. I think we ought to take a really strong look at, are we preparing people to do the surgeries that are necessary to get someone to no gross residual 70% and 85% of the time? Dr. Linda Duska: We are going to run out of time, but I want to address that and ask you a provocative question. So, I completely agree with what you said, that surgery is important. But I also think one of the reasons these patients in this study did so well is because all of the incredible new therapies that we have for patients. Because OS is not just about surgery. It is about surgery, but it is also about all of the amazing new therapies we have that you and others have helped us to get through clinical research. And so, how much of that do you think, like, for example, if you look at the PFS and OS rates from CHORUS and EORTC, I get it that they're, that they're not the same. It's different patients, different populations, can't do cross-trial comparisons. But the OS, as you said, in this study was 54 months and 48 months, which is, compared to 2010, we're doing much, much better. It is not just the surgery, it is also all the amazing treatment options we have for these patients, including PARP, including MIRV, including lots of other new therapies. How do you fit that into thinking about all of this? Dr. Kathleen Moore: I do think we are seeing, and we know this just from epidemiologic data that the prevalence of ovarian cancer in many of the countries where the study was done is increasing, despite a decrease in incidence. And why is that? Because people are living longer. Dr. Linda Duska: People are living longer, yeah. Dr. Kathleen Moore: Which is phenomenal. That is what we want. And we do have, I think, better supportive care now. PARP inhibitors in the frontline, which not many of these patients had. Now some of them, this is mainly in Europe, will have gotten them in the first maintenance setting, and I do think that impacts outcome. We do not have that data yet, you know, to kind of see what, I would be really interested to see. We do not do this well because in ovarian cancer, post-progression survival can be so long, we do not do well of tracking what people get when they come off a clinical trial to see how that could impact – you know, how many of them got another surgery? How many of them got a PARP? I think this group probably missed the ADC wave for the most part, because this, mirvetuximab is just very recently available in Europe. Dr. Linda Duska: Unless they were on trial. Dr. Kathleen Moore: Unless they were on trial. But I mean, I think we will have to see. 600 patients, I would bet a lot of them missed the ADC wave. So, I do not know that we can say we know what drove these phenomenal – these are some of the best curves we've seen outside of BRCA. And then coming back to your point about the BRCA population here, that is a really critical question that I do not know that we're ever going to answer. There have been hypotheses around a tumor that is driven by BRCA, if you surgically cytoreduced it, and then chemically cytoreduced it with chemo, and so you're starting PARP with nothing visible and likely still homogeneous clones. Is that the group we cured? And then if you give chemo first before surgery, it allows more rapid development of heterogeneity and more clonal evolution that those are patients who are less likely to be cured, even if they do get cytoreduced to nothing at interval with use of PARP inhibitor in the front line. That is a question that many have brought up as something we would like to understand better. Like, if you are BRCA, should you always just go for it or not? I do not know that we're ever going to really get to that. We are trying to look at some of the other studies and just see if you got neoadjuvant and you had BRCA, was anyone cured? I think that is a question on SOLO1 I would like to know the answer to, and I don't yet, that may help us get to that. But that's sort of something we do think about. You should have a fair number of them in TRUST. It wasn't a stratification factor, as I remember. Dr. Linda Duska: No, it wasn't. They stratified by center, age, and ECOG status Dr. Kathleen Moore: So you would hope with randomization that you would have an equal number in each arm. And they may be able to pull that out and do a very exploratory look. But I would be interested to see just completely hypothesis-generating what this looks like for the patients with BRCA, and I hope that they will present that. I know they're busy at work. They have translational work. They have a lot pending with TRUST. It's an incredibly rich resource that I think is going to teach us a lot, and I am excited to see what they do next. Dr. Linda Duska: So, outside of TRUST, we are out of time. I just want to give you a moment if there were any other messages that you want to share with our listeners before we wrap up. Dr. Kathleen Moore: It's an exciting time to be in GYN oncology. For so long, it was just chemo, and then the PARP inhibitors nudged us along quite a bit. We did move more patients, I believe, to the cure fraction. When we ultimately see OS, I think we'll be able to say that definitively, and that is exciting. But, you know, that is the minority of our patients. And while HRD positive benefits tremendously from PARP, I am not as sure we've moved as many to the cure fraction. Time will tell. But 50% of our patients have these tumors that are less HRD. They have a worse prognosis. I think we can say that and recur more quickly. And so the advent of these antibody-drug conjugates, and we could name 20 of them in development in GYN right now, targeting tumor-associated antigens because we're not really driven by mutations other than BRCA. We do not have a lot of things to come after. We're not lung cancer. We are not breast cancer. But we do have a lot of proteins on the surface of our cancers, and we are finally able to leverage that with some very active regimens. And we're in the early phases, I would say, of really understanding how best to use those, how best to position them, and which one to select for whom in a setting where there is going to be obvious overlap of the targets. So we're going to be really working this problem. It is a good problem. A lot of drugs that work pretty well. How do you individualize for a patient, the patient in front of you with three different markers? How do you optimize it? Where do you put them to really prolong survival? And then we finally have cell surface. We saw at ASCO, CDK2 come into play here for the first time, we've got a cell cycle inhibitor. We've been working on WEE1 and ATR for a long time. CDK2s may hit. Response rates were respectable in a resistant population that was cyclin E overexpressing. We've been working on that biomarker for a long time with a toxicity profile that was surprisingly clean, which I like to see for our patients. So that is a different platform. I think we have got bispecifics on the rise. So there is a pipeline of things behind the ADCs, which is important because we need more than one thing, that makes me feel like in the future, I am probably not going to be using doxil ever for platinum-resistant disease. So, I am going to be excited to retire some of those things. We will say, "Remember when we used to use doxil for platinum-resistant disease?" Dr. Linda Duska: I will be retired by then, but thanks for that thought. Dr. Kathleen Moore: I will remind you. Dr. Linda Duska: You are right. It is such an incredibly exciting time to be taking care of ovarian cancer patients with all the opportunities.  And I want to thank you for sharing your valuable insights with us on this podcast today and for your great work to advance care for patients with GYN cancers. Dr. Kathleen Moore: Likewise. Thanks for having me. Dr. Linda Duska: And thank you to our listeners for your time today. You will find links to the TRUST study and other studies discussed today in the transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. More on today's speakers:   Dr. Linda Duska  @Lduska Dr. Kathleen Moore Follow ASCO on social media:     @ASCO on X (formerly Twitter) ASCO on Bluesky   ASCO on Facebook     ASCO on LinkedIn     Disclosures of Potential Conflicts of Interest:    Dr. Linda Duska:   Consulting or Advisory Role: Regeneron, Inovio Pharmaceuticals, Merck, Ellipses Pharma  Research Funding (Inst.): GlaxoSmithKline, Millenium, Bristol-Myers Squibb, Aeterna Zentaris, Novartis, Abbvie, Tesaro, Cerulean Pharma, Aduro Biotech, Advaxis, Ludwig Institute for Cancer Research, Leap Therapeutics  Patents, Royalties, Other Intellectual Property: UptToDate, Editor, British Journal of Ob/Gyn  Dr. Kathleen Moore: Leadership: GOG Partners, NRG Ovarian Committee Chair Honoraria: Astellas Medivation, Clearity Foundation, IDEOlogy Health, Medscape, Great Debates and Updates, OncLive/MJH Life Sciences, MD Outlook, Curio Science, Plexus, University of Florida, University of Arkansas for Medical Sciences, Congress Chanel, BIOPHARM, CEA/CCO, Physician Education Resource (PER), Research to Practice, Med Learning Group, Peerview, Peerview, PeerVoice, CME Outfitters, Virtual Incision Consulting/Advisory Role: Genentech/Roche, Immunogen, AstraZeneca, Merck, Eisai, Verastem/Pharmacyclics, AADi, Caris Life Sciences, Iovance Biotherapeutics, Janssen Oncology, Regeneron, zentalis, Daiichi Sankyo Europe GmbH, BioNTech SE, Immunocore, Seagen, Takeda Science Foundation, Zymeworks, Profound Bio, ADC Therapeutics, Third Arc, Loxo/Lilly, Bristol Myers Squibb Foundation, Tango Therapeutics, Abbvie, T Knife, F Hoffman La Roche, Tubulis GmbH, Clovis Oncology, Kivu, Genmab/Seagen, Kivu, Genmab/Seagen, Whitehawk, OnCusp Therapeutics, Natera, BeiGene, Karyopharm Therapeutics, Day One Biopharmaceuticals, Debiopharm Group, Foundation Medicine, Novocure Research Funding (Inst.): Mersana, GSK/Tesaro, Duality Biologics, Mersana, GSK/Tesaro, Duality Biologics, Merck, Regeneron, Verasatem, AstraZeneca, Immunogen, Daiichi Sankyo/Lilly, Immunocore, Torl Biotherapeutics, Allarity Therapeutics, IDEAYA Biosciences, Zymeworks, Schrodinger Other Relationship (Inst.): GOG Partners

In this conversation, Dr. Iman Farajallah shares her profound experiences and insights as a psychologist working with trauma, particularly in war zones like Gaza. She discusses her personal background, the impact of war trauma on children, and her efforts to give a voice to those affected. The conversation also touches on the challenges of mental health support in Gaza and the concept of complex continuous trauma, highlighting the ongoing struggles faced by the Palestinian population. This conversation delves into the profound and complex trauma experienced by the population of Gaza, particularly focusing on the impact on children. The discussion highlights the continuous nature of trauma, the intergenerational effects, and the parallels with other marginalized communities. Dr. Farajallah shares insights from her work training first responders and supporting refugees, as well as her personal journey of healing through spirituality. Watch on YouTube: https://youtu.be/-ZcfFTPEuro Continuing Education Credits (https://www.cbiconsultants.com/shop) BACB: 1.5 Ethics IBAO:  1.5  Cultural QABA: 1.5  General CBA:    1.5  Cultural Diversity  Follow us! Instagram: https://www.instagram.com/behaviourspeak/ LinkedIn:  https://www.linkedin.com/in/behaviourspeak/ Contact: LinkedIn https://www.linkedin.com/in/dr-iman-farajallah-psyd-6aa190149/ Links: My Life Is a War: Voices of Traumatized Palestinian Children under Israeli Occupation https://a.co/d/cUFdLEA Articles Mentioned: Farajallah, I. (2022). Continuous traumatic stress in Palestine: The psychological effects of the occupation and chronic warfare on Palestinian children. World Social Psychiatry, 4(2), 112-120. Farajallah, I., & Farajallah, H. (2024). Challenges in access to safe drinking water and its impact on maternal and child health in Gaza. Anatolian Clinic the Journal of Medical Sciences, 29(Special Issue on Gaza), 52-65. Farajallah, I. (2024). Behind the Rubble: Psychological trauma of wars and human rights abuses on women and children in Gaza. Anatolian Clinic the Journal of Medical Sciences, 29(Special Issue on Gaza), 119-136. Farajallah, I. (2018). Children of War: Psychological Impacts of War and Postwar Trauma on the Palestinian Children in the Gaza Strip (Doctoral dissertation, Sofia University). Related Behaviour Speak Episodes Episode 239: Supporting Refugee and Migrant Students Amid Climate and War-Induced Displacement with Dr. Diana Diaków https://www.behaviourspeak.com/e/episode-239-supporting-refugee-and-migrant-students-amid-climate-and-war-induced-displacement-with-dr-diana-diakow/ Episode 232: Behaviour Analysis in Sudan with Salma Abdelrahmanabdalla https://www.behaviourspeak.com/e/episode-232-behaviour-analysis-in-sudan-with-salma-abdelrahmanabdalla-med-iba-qba/ Episode 197: Understanding Moral Injury with Dr. C. Richard Spates https://www.behaviourspeak.com/e/episode-197-understanding-moral-injury-with-dr-c-richard-spates/ Episode 191: Behaviour Analysis in Belarus with Анна Калиновская ((Hanna Kalinouskaya), M.A., BCBA, IBA  https://www.behaviourspeak.com/e/behaviouranalysis-in-belaruswith-hannakalinouskaya-bcba-iba/ Episode 184 Behavior Analysis in Ukraine with Alla Moskalets https://www.behaviourspeak.com/e/episode-184-behavior-analysis-in-ukraine-with-alla-moskalets/ Episode 176: Religion, Spirituality, and Mental Health with Dr. Janice Parker https://www.behaviourspeak.com/e/episode-176-religion-spirituality-and-mental-health/ Episode 139: Threads of Hope: Addressing Trauma Amid War and Civil Discord with Sawsan Razzouk, M.A., BCBA https://www.behaviourspeak.com/e/episode-139threads-of-hope-addressing-trauma-amid-war-and-civil-discord-with-sawsan-razzouk-ma-bcba/

On today's show, we hear about new research from the University of Arkansas for Medical Sciences that could help explain why the Marshallese community faces higher rates of chronic health conditions. We also learn about the influence of Lucinda Williams' music. Plus, a different kind of Veterans Day celebration in Gentry this weekend.

Obesity is a serious and costly chronic disease that has been widely recognized as a public health epidemic. Although there are accessible, affordable, and straightforward tools to address it in individuals and broader communities, obesity remains a widespread public health threat that increases one's risk for developing other conditions such as heart disease, type 2 diabetes, and some forms of cancer. Trust for America's Health recently published its “State of Obesity 2025” report, which notes that Arkansas has the fifth-highest adult obesity rate in the nation. To learn more about the state of obesity in Arkansas and policy options to address it, we're joined on this episode of the Wonks at Work podcast by Dr. Arlo Kahn, ACHI's medical director and a professor in the Department of Family and Preventive Medicine at the University of Arkansas for Medical Sciences who has dedicated much of the last quarter century to addressing this issue.

With Carsten W Israel, Bethel-Clinic, Bielefeld - Germany, and Stefan Simovic, Faculty of Medical Sciences, University of Kragujevac - Serbia. During this podcast, Carsten Israel and Stefan Simovic will discuss how electrophysiology can adopt sustainable practices while maintaining high-quality patient care. 

On Today's episode of Transforming Healthcare with Dr. Wael Barsoum, we have special guests Dr. Jason Sansone and Benjamin Jarvis. Dr. Jason Sansone, MD, is a board-certified, fellowship-trained orthopedic surgeon and the President of Orthopedic & Spine Centers of Wisconsin. He specializes in spine surgery and orthopedic traumatology. A Wisconsin native, Dr. Sansone earned his Doctor of Medicine from the University of Wisconsin School of Medicine and Public Health and completed his orthopedic surgery residency at the University of Wisconsin Hospital and Clinics. He also holds a Bachelor of Science in Medical Sciences from the University of Wisconsin. He is a Fellow of the American Academy of Orthopedic Surgeons (AAOS) and an active member of the Wisconsin Medical Society. Dr. Sansone's specialty fellowship training includes spine surgery, enabling him to provide advanced care for conditions affecting the spine, as well as orthopedic traumatology, which encompasses both operative and non-operative care of complex fractures. Benjamin Jarvis is the Executive Vice President of Wisconsin Operations at Healthcare Outcomes Performance Co. Benjamin previously held various administrative and managerial roles in the healthcare industry, including Administrator of Surgical Operations at SSM Health, Practice Manager at NorthShore University HealthSystem, and Account Manager at Aerotek Scientific. Benjamin holds a Master of Science in Health Systems Management from RUSH University and a Bachelor's degree in Medical Microbiology & Immunology, Biology from the University of Wisconsin-Madison. Join us as we talk about the successes and pitfalls of their journey to starting an orthopedic practice from scratch.

In Episode 2 of this season, we explore the evolution of beauty (especially in birds) and the beauty of innovation, with guest Matt Ridley.Matt Ridley's books have sold over a million copies, been translated into 31 languages and won several awards. His books include The Red Queen, Genome, The Rational Optimist, The Evolution of Everything, How Innovation Works, and Viral: the search for the origin of covid-19 (co-authored with Alina Chan). His latest book is Birds, Sex, and Beauty.He served the House of Lords between 2013 and 2021 and served on the science and technology select committee and the artificial intelligence select committee.He was founding chairman of the International Centre for Life in Newcastle. He created the Mind and Matter column in the Wall Street Journal in 2010 and was a columnist for the Times 2013-2018. He is a fellow of the Royal Society of Literature and of the Academy of Medical Sciences, and a foreign honorary member of the American Academy of Arts and Sciences. He lives in Northumberland.In this episode, we talk about:The myth of “disruptive innovation” and the overlooked beauty of incremental progressThe real relationship between basic science and technologyWhy Ridley still calls himself a “rational optimist”Why freedom, not brilliance, is the secret sauce of innovationHow universities and industry can collaborate to keep creativity aliveTo learn more about Matt's work, you can find him at: https://www.mattridley.co.uk/ Books and resources mentioned:Birds, Sex and Beauty (by Matt Ridley) How Innovation Works (by Matt Ridley)The Rational Optimist (by Matt Ridley)The Mating Mind (by Geoffrey Miller)The Descent of Man (by Charles Darwin)The Genetical Theory of Natural Selection (by Ronald Fisher)Survival of the Prettiest: The Science of Beauty (by Nancy Etcoff)The Rational Optimist Society – rationaloptimistsociety.com This season of the podcast is sponsored by Templeton Religion Trust.Support the show

“At some point, feeling good wins over old thoughts.” –VJ HamiltonStruggling with autoimmune disease — or uncomfortable symptoms that you've just learned to live with? What if you could reverse your symptoms? I'm so excited to talk with VJ Hamilton, registered nutritionist and a functional medicine practitioner who specializes in autoimmune disease.I was diagnosed with celiac disease fairly late in life. When I was diagnosed, it just made so much sense and explained so many things. It also led to change. And that can be hard to navigate on your own.Perimenopause and menopause symptoms and those of autoimmune diseases — like brain fog, joint aches, and fatigue — can be signs of both. Plus shifts in hormones can certainly trigger changes or unmask hidden inflammation. Testing and treatment can help.We talk about: Autoimmune disease 101 — what we're actually talking aboutTriggers vs. root causes and how to find the root causeHow to advocate for yourself with doctors and what other practitioner you might want to seeSimple changes you can make to improve your healthFocus not on what you have to cut out for food or what exercise you have to do, but what you need and what you likeEating whole foods instead of prepared meals and how to navigate restaurants and special eventsABOUT VJVJ Hamilton is the founder of The Autoimmunity Nutritionist and an expert in autoimmune disease, specialising in skin disorders, chronic fatigue, joint health, and digestive issues for both men and women.As a Registered Nutritionist with a Medical Science degree (BSc) in Biochemistry & Immunology and having completed the full certification programme at the renowned Institute for Functional Medicine, VJ uses evidence-based nutritional therapies to support her clients in transforming their health.LINKShttps://theautoimmunitynutritionist.com/https://www.instagram.com/theautoimmunitynutritionist/ https://www.linkedin.com/in/theautoimmunitynutritionist/ DOABLE CHANGESAt the end of every episode, we share three doable changes, so you can take what you've heard and put it into action. Action is where change happens. But here's the thing: when we have a goal, a wish, a desire bubbling up in us, it can feel really huge. Sometimes we stop ourselves in our tracks based on how huge our desire feels. Change needs action, but it doesn't need huge action. When we focus on the next step, the next Doable Change that we can integrate into our lives, we don't get stuck and we create momentum. Choose one Doable Change that resonates with you today and really play with it. Fit it into your life, your days, make it work for you — then move on to your next Doable Change. Here are Three Doable Changes from this conversation: MAKE A LIST OF THINGS YOU LOVE TO DO. Changing your lifestyle doesn't have to be terrible! Make a list of things you love to do. Ways you like to be active, rest, connect with others. Make a list of things that make you feel good! Plan for more of those things in your life. That might look like swapping dancing for a gym session or eating food that gives you energy or going to bed on time.RESET IDEAS AROUND FOOD. Here are a few ways to try this Doable Change. First, instead of asking, “What do I have to cut out?” think about what foods you can...

In this week's episode of The Energy Code, Dr. Mike Belkowski returns to the roots of his red-light research—breaking down four powerful new studies that reveal just how multifaceted photobiomodulation truly is.   From boosting mitochondrial function and improving sleep to reducing chronic pain and supporting mental health, Dr. Mike explores the data behind red and near-infrared light and what it means for athletes, biohackers, and anyone pursuing optimal energy and longevity.   Dr. Mike dives into: A systematic review on whole-body red-light therapy for exercise performance and recovery The connection between melatonin production and mitochondria How red light can relieve fibromyalgia pain and calm an over-sensitized nervous system A study showing transcranial near-infrared light can reduce anxiety, depression, and drug cravings The latest FDA-approved findings for age-related macular degeneration   This deep-dive connects the science to real-world strategies—helping listeners understand how to personalize light therapy for maximum mitochondrial, mental, and cellular benefits. Key Topics Covered The myth of “more light equals better results” Why localized red-light therapy outperforms full-body setups for muscle recovery How red light enhances melatonin and circadian alignment for deeper sleep Using red light to calm the nervous system and reduce systemic inflammation New clinical results showing brain-based red light reduces depression and cravings FDA authorization for light therapy in macular degeneration How to calculate your optimal dosage with BioLight's free treatment calculator Key Quotes from Dr. Mike Belkowski   “Your mitochondria are environmental sensors — when they see the wrong light, they know it.” “Localized light on target tissue beats whole-body treatments when it comes to performance.” “Red light therapy can calm an overstimulated nervous system and retrain your pain pathways.” “The more we standardize light protocols, the more consistent and powerful the results will be.” Episode Timeline   00:00 – Morning sunrise + intro 02:30 – What's new in the mitochondrial matrix 07:00 – BioMinerals discount announcement 08:00 – Study #1: Whole-body red light for performance 15:00 – Why dosage and location matter 16:00 – Red light, melatonin & sleep quality 19:00 – Red light's stress-reducing parasympathetic effects 23:00 – Study #2: Fibromyalgia and chronic pain reduction 30:00 – How red light calms sensitized nerves 33:00 – Study #3: Transcranial red light for mood & craving 36:00 – Near-infrared brain protocols explained 37:00 – Study #4: Red light for macular degeneration 44:00 – Why research results can appear contradictory 46:00 – Final thoughts: dosage, nuance, and mitochondrial optimization

In Episode 2 of this season, we explore the evolution of beauty (especially in birds) and the beauty of innovation, with guest Matt Ridley.Matt Ridley's books have sold over a million copies, been translated into 31 languages and won several awards. His books include The Red Queen, Genome, The Rational Optimist and The Evolution of Everything. His book on “How Innovation Works” was published in 2020, and "Viral: the search for the origin of covid-19", co-authored with Alina Chan, was published in 2021.He served the House of Lords between 2013 and 2021 and served on the science and technology select committee and the artificial intelligence select committee.He was founding chairman of the International Centre for Life in Newcastle. He created the Mind and Matter column in the Wall Street Journal in 2010 and was a columnist for the Times 2013-2018. He is a fellow of the Royal Society of Literature and of the Academy of Medical Sciences, and a foreign honorary member of the American Academy of Arts and Sciences.He lives in Northumberland.In this episode, we talk about:How Ridley's childhood fascination with birds led him to study evolutionThe courtship rituals of black grouse and the surprising role of female choiceHow Ronald Fisher's “sexy sons” hypothesis changed everythingWhat bowerbirds can teach us about aesthetics and artSexual selection as a driver of creativity, humor, and the human brainTo learn more about Matt's work, you can find him at: https://www.mattridley.co.uk/ Books and resources mentioned:Birds, Sex and Beauty (by Matt Ridley) How Innovation Works (by Matt Ridley)The Rational Optimist (by Matt Ridley)The Mating Mind (by Geoffrey Miller)The Descent of Man (by Charles Darwin)The Genetical Theory of Natural Selection (by Ronald Fisher)Survival of the Prettiest: The Science of Beauty (by Nancy Etcoff)The Rational Optimist Society – rationaloptimistsociety.com This season of the podcast is sponsored by Templeton Religion Trust.Support the show

Dr. Uri Tabori is a Staff Physician in the Division of Haematology/Oncology, Senior Scientist in the Genetics & Genome Biology program, and Principal Investigator of The Arthur and Sonia Labatt Brain Tumour Research Centre at The Hospital for Sick Children (SickKids). Uri is also a Professor in Paediatrics and Associate Professor in the Institute of Medical Sciences at the University of Toronto. Uri works as a physician treating kids with cancer, particularly brain tumors. Through his research, he is working to identify drugs and make new discoveries that may cure cancers or improve patients' lives. When he's not hard at work in the lab or clinic, Uri enjoys spending time with his family, watching American football, and exploring the wilderness of Canada. He is especially fond of canoeing and canoe camping with his family. He received his MD from the Hadassah School of Medicine of Hebrew University in Israel. Afterwards, he completed a Rotating Internship and his Residency in Pediatrics at the Sorasky Medical Center in Israel. Next, Uri accepted a Fellowship in Pediatric Hematology and Oncology at the Sheba Medical Center in Israel. He served as a Staff Physician in Pediatric Hematology and Oncology at The Sheba Medical Center for about a year before accepting a Research and Clinical Fellowship at The Hospital for Sick Children in Canada SickKids where he remains today. Over the course of his career, Uri has received numerous awards and honors, including the Early Researcher Award from the Ontario Ministry of Development and Innovation, the New Investigator Award from the Canadian Institute of Health Research, the Junior Physician Research Award from the University of Toronto Department of Pediatrics, The New Investigator Award from the Terry Fox Foundation, A Eureka! new investigator award from the International Course of Translational Medicine, A Merit Award from the American Society of Clinical Oncology Annual Meeting, and The Young Investigator Award from the Canadian Neuro-Oncology Society. In our interview, Uri shares more about his life, science, and clinical care.

After 35 years in medicine, Dr. Joe Jacko has seen it all - and he's ready to tell you what the medical industry doesn't want you to know. In our conversation, he breaks down why patients only get half the information they need, how drug studies use misleading statistics, and why evidence-based medicine has become cookbook medicine driven by insurance profits. But this isn't just criticism, it's empowerment. We discuss Blue Zone residents living to 100 without knowing medical science, why purpose can outweigh poor health markers, and practical strategies for advocating for yourself in medical appointments. Dr. Jacko now runs a comprehensive wellness clinic proving that lifestyle medicine works better than pills for chronic conditions. Key topics: patient empowerment, lifestyle medicine, autoimmune healing, finding integrative doctors, Blue Zones longevity secrets, and why gentle movement beats over-exercising.For the complete show notes, links and transcript visit: inspiredliving.show/214

Fear is one of the earliest emotions to have evolved. Most vertebrates – and possibly some invertebrates – show fear when they are threatened. At its most core, fear keeps us alive, helping us flee from predators or avoid dangerous environments. But why does this process sometimes backfire, leaving us paralysed by otherwise harmless phobias? And why do so many people deliberately seek out fearful situations, from horror movies to parachute jumps, when instinct tells us to do the opposite? Can understanding the biology of fear help us conquer it, or simply make us more vulnerable to its impact?This lecture was recorded by Robin May on the 1st of October 2025 at Bernards Inn Hall, LondonProfessor of Infectious Disease at the University of Birmingham, and (interim) Chief Scientist at the UK Health Security Agency, Robin May was appointed Gresham Professor of Physic in May 2022. Between July 2020 and September 2025 he served as Chief Scientific Adviser at the Food Standards Agency (FSA). Professor May's early training was in Plant Sciences at the University of Oxford, followed by a PhD on mammalian cell biology at University College London and the University of Birmingham. After postdoctoral research on gene silencing at the Hubrecht Laboratory, The Netherlands, he returned to the UK in 2005 to establish a research program on human infectious diseases. He was Director of the Institute of Microbiology and Infection at the University of Birmingham from 2017-2020. Professor May continues his work on Infectious Disease at the University of Birmingham. A Fellow of the Academy of Medical Sciences, Wolfson Royal Society Research Merit Fellow and Fellow of the American Academy of Microbiology, Professor May specialises in research into human infectious diseases, with a particular focus on how pathogens survive and replicate within host organisms.As the FSA's Chief Scientific Adviser, Professor May provides expert scientific advice to the UK government and plays a critical role in helping to understand how scientific developments will shape the work of the FSA, as well as the strategic implications of any possible changes.The transcript of the lecture is available from the Gresham College website: https://www.gresham.ac.uk/watch-now/why-fearGresham College has offered free public lectures for over 400 years, thanks to the generosity of our supporters. There are currently over 2,500 lectures free to access. We believe that everyone should have the opportunity to learn from some of the greatest minds. To support Gresham College's mission, please consider making a donation: https://www.gresham.ac.uk/get-involved/support-us/make-donation/donate-today Website:  https://gresham.ac.ukX: https://x.com/GreshamCollegeFacebook: https://facebook.com/greshamcollegeInstagram: https://instagram.com/greshamcollegeBluesky: https://bsky.app/profile/greshamcollege.bsky.social TikTok: https://www.tiktok.com/@greshamcollegeSupport Us: https://www.gresham.ac.uk/get-involved/support-us/make-donation/donate-todaySupport the show

Bridging Science and Spirit: Mind Wellness & Transformation with Niharika RajnalaHost: Victoria JohnsonGuest: Niharika Rajnala, M.Sc., PhD (Candidate) – Health Science Professional, Certified Heal Your Life® Coach, Mind Wellness & Transformation CoachIn this empowering episode, Victoria Johnson welcomes Niharika Rajnala, a passionate Health Science Professional and Mind Wellness Coach based in Victoria, BC, Canada. With over 13 years of experience spanning mind wellness, clinical research, public health, academic research, and medical writing, Niharika shares how she blends Louise Hay's transformational philosophy with her scientific background to help others heal from the inside out.Niharika Rajnala holds a Master's Degree in Medical Science and is currently pursuing her PhD. She is a Researcher at a leading cancer clinic, contributing to advancements across multiple therapeutic areas:Oncology: Lung Cancer, Cervical Cancer, Breast CancerNeurochemistry: Alzheimer's DiseaseImmunology: PsoriasisInfectious Diseases: Pediatric HIVHer exceptional work has earned her several international awards and recognition in Research & Development and the Pharmaceutical Industry.She offers insights into the connection between science and spirituality, the power of affirmations, and how to create mental and emotional balance through intentional daily practices.“The point of power is in the present moment.” – Louise HayAs a Certified Heal Your Life® Coach, Niharika is passionate about mind wellness, transformation, and emotional healing. Through her YouTube channel, she shares guided meditations, affirmations, and healing practices, inspiring a global audience to live consciously and joyfully.Science Meets Soul: How medical research and Louise Hay's teachings work hand-in-hand to promote holistic healing.Affirmations as Medicine: Using positive thought to reframe stress and enhance mental clarity.Mind Wellness Practices: Simple daily rituals for balance, resilience, and self-love.Global Impact: Bringing healing to people worldwide through digital content and compassionate coaching.Presence and Power: Returning to the moment to access peace, awareness, and possibility.“I bring together medical science and mind wellness to help people transform from the inside out.” – Niharika Rajnala“The point of power is in the present moment.” – Louise Hay“Our minds are powerful allies in healing when guided by love, not fear.” – Niharika RajnalaGround Yourself: Pause and take three slow breaths before your next task. Affirm the Positive: Repeat, “I am healthy, whole, and complete.” Learn & Reflect: Visit Niharika's YouTube channel and explore a guided meditation that speaks to your current season.⁠YouTube⁠⁠LinkedIn ⁠To learn more about Heal Your Life® Coach training with Victoria Johnson PhD, ⁠please visit our website. ⁠

Bridging Science and Spirit: Mind Wellness & Transformation with Niharika RajnalaHost: Victoria JohnsonGuest: Niharika Rajnala, M.Sc., PhD (Candidate) – Health Science Professional, Certified Heal Your Life® Coach, Mind Wellness & Transformation CoachIn this empowering episode, Victoria Johnson welcomes Niharika Rajnala, a passionate Health Science Professional and Mind Wellness Coach based in Victoria, BC, Canada. With over 13 years of experience spanning mind wellness, clinical research, public health, academic research, and medical writing, Niharika shares how she blends Louise Hay's transformational philosophy with her scientific background to help others heal from the inside out.Niharika Rajnala holds a Master's Degree in Medical Science and is currently pursuing her PhD. She is a Researcher at a leading cancer clinic, contributing to advancements across multiple therapeutic areas:Oncology: Lung Cancer, Cervical Cancer, Breast CancerNeurochemistry: Alzheimer's DiseaseImmunology: PsoriasisInfectious Diseases: Pediatric HIVHer exceptional work has earned her several international awards and recognition in Research & Development and the Pharmaceutical Industry.She offers insights into the connection between science and spirituality, the power of affirmations, and how to create mental and emotional balance through intentional daily practices.“The point of power is in the present moment.” – Louise HayAs a Certified Heal Your Life® Coach, Niharika is passionate about mind wellness, transformation, and emotional healing. Through her YouTube channel, she shares guided meditations, affirmations, and healing practices, inspiring a global audience to live consciously and joyfully. Science Meets Soul: How medical research and Louise Hay's teachings work hand-in-hand to promote holistic healing.Affirmations as Medicine: Using positive thought to reframe stress and enhance mental clarity.Mind Wellness Practices: Simple daily rituals for balance, resilience, and self-love.Global Impact: Bringing healing to people worldwide through digital content and compassionate coaching.Presence and Power: Returning to the moment to access peace, awareness, and possibility.“I bring together medical science and mind wellness to help people transform from the inside out.” – Niharika Rajnala“The point of power is in the present moment.” – Louise Hay“Our minds are powerful allies in healing when guided by love, not fear.” – Niharika RajnalaGround Yourself: Pause and take three slow breaths before your next task. Affirm the Positive: Repeat, “I am healthy, whole, and complete.” Learn & Reflect: Visit Niharika's YouTube channel and explore a guided meditation that speaks to your current season.YouTubeLinkedIn To learn more about Heal Your Life® Coach training with Victoria Johnson PhD, please visit our website. If you enjoyed this episode:✅ Subscribe to the Heal Your Life Talk Radio Show

“Toxins are everywhere — in our food, water, and air. They damage our mitochondria, disrupt metabolism, and open the door to disease.” —Dr. Richard ChengIn this episode of the Real Health Podcast, Ron Hunninghake, MD, sits down with Richard Cheng, MD, PhD, ABAARM — physician, researcher, and editor of Orthomolecular Medicine News Service — to explore how environmental toxins and mitochondrial dysfunction are driving today's rise in chronic illness and cancer.Dr. Cheng shares how decades of research have revealed the link between toxins, aging, and cancer and why supporting mitochondrial health and reducing environmental exposure may be one of the most effective preventive strategies in modern medicine.

Listen to JCO Global Oncology's Art of Global Oncology article, "Whispers After the Cure: Reflections on Marriage and Malignancy in India” by Dr. Vangipuram Harshil Sai, who is a fourth semester medical student at All India Institute of Medical Sciences. The article is followed by an interview with Harshil Sai and host Dr. Mikkael Sekeres. Sai shares his personal reflection of a visit which transformed into an education in silence, stigma, and the unseen aftermath of survivorship for young women in India. TRANSCRIPT Narrator: Whispers After the Cure: Reflections on Marriage and Malignancy in India, Vangipuram, Harshil Sai   A Summer Afternoon and A Story That Stayed The summer break of my fourth semester of medical school offered a fleeting reprieve from the relentless immersion in textbooks and caffeine-fueled study sessions. I had envisioned a few weeks of rest—a pause from the algorithms of diagnosis and the grind of multiple-choice questions that had become my daily rhythm. But one humid afternoon altered that plan. I accompanied my mother—a senior medical oncologist—to her clinic in a Tier 2 city in Southern India. Over the years, I had seen her not just as a clinician but as a quiet force of empathy. She was one of those remarkable physicians who listened not just to symptoms but also to stories. Her practice was rooted in presence, and her calm resilience often made my academic anxieties seem trivial. I settled into a corner chair in the waiting area, where the air was tinged with antiseptic and that uncomfortable waiting room stillness—an alert hush between uncertainty and news. Patients waited in quiet constellations: a man turning the same page of a newspaper, a teenage girl watching her intravenous drip as if it held answers, and a couple clasping hands without meeting eyes. It was in this atmosphere of suspended quiet that Aarthi entered. She was a young woman whose presence was composed yet tentative. Her story would become a quiet inflection point in my understanding of medicine. She was 24 years old, embodying the aspirations tied to a recent engagement. A postgraduate in English literature and a practicing psychologist; she carried herself with a rare blend of intellect, poise, and cultural grace that, in the eyes of many families, made her a deeply desirable bride. Her sari was immaculately draped, her posture measured and calm, yet in the way her fingers intertwined and her eyes briefly lowered, there was a trace of vulnerability—a shadow of the turmoil she carried within. She came alone that day, stepping into the waiting room with a composed demeanor that only hinted at the weight she bore in silence. What began as a day to observe became the beginning of something far more enduring: a glimpse into how healing extends beyond treatment—and how survival, though silent, often speaks the loudest. The Diagnosis That Changed the Wedding The consultation was precipitated by a clinical presentation of persistent neck fullness, low-grade fevers, and drenching night sweats, which had prompted a fine-needle aspiration before her visit. The atmosphere in the room held an implicit gravity, suggesting a moment of significant change. My mother, with her characteristic composure, initiated a diagnostic process with a positron emission tomography-computed tomography and biopsy. As usual, her steady presence provided reassurance amid the uncertainty. A week later, the diagnosis of classic Hodgkin lymphoma, stage IIB, was confirmed. Rapid initiation of ABVD chemotherapy would provide an almost certain pathway to remission and an excellent prognosis. Yet, this clinical assurance did not extend to personal tranquility. Aarthi made a deliberate choice to share the diagnosis with her fiancé—a considerate and empathetic individual from a well-regarded family. Their wedding preparations were already underway with gold reserves secured and a vibrant WhatsApp group of 83 members chronicling the countdown to their big day. Shortly thereafter, a prolonged silence settled, eventually broken by a call from a family member—not the fiancé—indicating that the family had decided to terminate the engagement because of apprehensions about future stability. The union dissolved without public discord, leaving Aarthi to navigate the subsequent journey independently. As expected, 6 months of chemotherapy culminated in a clean scan. Her physical health was restored, but an emotional chasm remained, unrecorded by clinical metrics. Yet beneath that silence was a quiet resilience—a strength that carried her through each cycle of treatment with a resolve as steady as any celebrated elsewhere. The regrowth of her hair prompted a conscious decision to trim it shorter, seemingly an assertion of autonomy. Her discourse on the illness shifted to the third person, suggesting a psychological distancing. Her reactions to inquiries about the terminated engagement were guarded. She would yield only a restrained smile, which intimated a multifaceted emotional response. Her remission was certain, yet the world she stepped back into was layered with quiet hurdles—social, cultural, and unseen—barriers far more intricate than the disease itself. Survivorship Without A Map In the weeks that followed Aarthi's diagnosis, I began to notice a quiet but consistent pattern in the oncology clinic—one that extended beyond medical recovery into the unspoken social aftermath. Among young, unmarried women in India, survivorship often came with a parallel challenge of navigating shifts in how they were perceived, particularly as marriage prospects. In Indian families where marital status is closely tied to stability and future security, a woman with a cancer history, even after complete remission, somehow came to be quietly perceived as less suitable. Proposals that had once moved forward with confidence were paused or reconsidered after disclosure. In some cases, financial discussions came with requests for additional support framed as reassurance rather than rejection. These changes were seldom explicit. Yet, across time, they pointed to a deeper uncertainty—about how survivorship fits into the expectations of traditional life scripts. For women like Aarthi, the narrative shifted toward caution. There were subtle inquiries about reproductive potential or disease recurrence and private deliberations over disclosure during matrimonial discussions, even within educated circles. Meanwhile, my observation of the disparity in how survivorship was interpreted across genders in our country left a profound mark on me. A 31-year-old male investment banker who had recovered from testicular cancer was hailed in local media as a testament to fortitude. Male patients seemed to gain social capital from their cancer journeys. This suggested a cultural framework where female value was quietly reassessed, influencing their post-treatment identity through unstated societal perceptions. Digital Ghosting and the New Untouchability Within the digital landscape of curated profiles and algorithmic matchmaking, the reassessment of female survivorship acquired a new dimension. In one instance, a sustained exchange of text messages ended abruptly following the mention of cancer remission. The final message remained unanswered. This form of silent disengagement—subtle, unspoken, and devoid of confrontation—highlighted how virtual spaces can compound post-treatment vulnerability. Designed to foster connection, these platforms sometimes amplified social distance, introducing a modern form of invisibility. Similar to employment status or religion, a cancer history has become another addition to a checklist used to evaluate compatibility. When Medicine Ends, but Society Does Not Begin As a medical student, I felt a growing discomfort. Our curriculum equips us to manage treatment protocols and survival metrics but rarely prepares us for the intangible burdens that persist after cure. What captures the weight of a canceled engagement? What framework supports the quiet reconstruction of identity after remission? Aarthi's path, echoed by many others, revealed a dissonance that medicine alone could not resolve. The challenge was not solely the illness but the reality that she was now unqualified to return to her normal life. Medicine delivers clean scans and structured follow-up, but social reintegration is less defined. In that space between biological recovery and social acceptance, cancer survivors often stand at the edge of wholeness—clinically well but navigating a quieter uncertainty. A Different Ending Two years later, Aarthi's journey took a quiet turn. At a spiritual retreat in Bengaluru, she met an ear, nose, and throat resident who had lost his father to lung cancer. Their connection, shaped by shared experiences, evolved into a partnership grounded in empathy and mutual respect. They married the following year. Their invitation carried a brief but powerful line: “Cancer Survivor. Love Thriver. Come celebrate both.” Today, they comanage a private hospital in Hyderabad. Aarthi leads psycho-oncology services, whereas her partner performs surgeries. He often notes that her presence brings a calm to the clinic that no medication can replicate. Aarthi's journey continues to guide me as I progress through my medical training, reminding me that cure and closure often follow separate paths. Healing, I have come to understand, extends beyond the clinic. It often unfolds in quieter spaces where scans no longer guide us. The real curriculum in oncology lies not only in staging and response rates but in recognizing the many transitions—social, emotional, and cultural—that survivors must navigate long after treatment has concluded. Social stigma is often a second metastasis—undetectable by imaging but present in tone, hesitation, and traditions that quietly redefine survivorship. For many women of marriageable age, treatment marks not the end of struggle but the start of another kind of uncertainty. These survivors carry wounds that do not bleed. Yet, they persist, navigate, and redefine strength on their own terms. Aarthi's quiet resilience became a point of reckoning for me, not as a medical case, but as a guide. Her story is not one of illness alone, but of dignity quietly reclaimed. “Out of suffering have emerged the strongest souls; the most massive characters are seared with scars.”—Khalil Gibran.   Mikkael Sekeres: Welcome back to JCO's Cancer Stories: The Art of Oncology. This ASCO podcast features intimate narratives and perspectives from authors exploring their experiences in oncology. I'm your host, Mikkael Sekeres. I'm professor of medicine and chief of the Division of Hematology at the Sylvester Comprehensive Cancer Center, University of Miami. In oncology, we often focus on treatment and a way to find a cure. But what about the expectations and challenges a patient may face from their diagnosis, and even discrimination, especially in different cultures? Today, we're going to examine that space with Harshil Vangipuram, a medical student from India whose JCO Global Oncology article, "Whispers After the Cure: Reflections on Marriage and Malignancy in India," touches on this complexity after treatment. Harshil, thank you for contributing to JCO Global Oncology and for joining us to discuss your article. Harshil Vangipuram: Thank you for having me, Dr. Sekeres. I was raised by a family of oncologists, my mother being a senior medical oncologist and father a senior radiation oncologist. I had exposure to contrasting worlds, which were resource constrained and a cutting edge technology world. And I have unfulfilled curiosity, and I'm still learning, forming ideals. I also see patients as my teachers, so I think that might be helpful. Mikkael Sekeres: Thank you so much for a little bit of that background. So, tell us a little bit about your journey through life so far. Where were you born and where did you do your education? Harshil Vangipuram: I was born in a state called Gujarat in the western part of India. My father got transferred to the southern part of India, so I did my education there. That's it, yeah. Mikkael Sekeres: Okay. That's enough. You're not that old. You haven't had the sort of training and final job that a lot of us have gone through. So, what about your story as a writer? How did you first get interested in writing, and how long have you been writing reflective or narrative pieces? Harshil Vangipuram: I read some books from Indian authors and from foreign, too. And they actually inspired me how patient care was being seen around globally. I always used to carry a hand note. I used to write what I used to see in the clinical postings here at AIIMS. And actually, journaling started as a stress relief for me, and slowly, after hearing patients' stories, it almost became an obligation to write about them. Mikkael Sekeres: Obligation, you use that word, which is such an interesting one. How did writing become an obligation? What did you feel obliged to do when writing about some of the patients you were seeing for the first time? Harshil Vangipuram: Many of them were having struggles which were not seen by everybody. And I got astonished by their confidence and resilience in those situations. So, I thought that I should write about them so that everybody knows about it. And these social stigmas were never talked by anyone around them. So, I felt that if I could voice them, others might eventually know about them. So, that's pretty much the reason I wrote. Mikkael Sekeres: It's so interesting. The people we meet every single day, particularly in hematology oncology, bring such fascinating backgrounds to us, and they're backgrounds that may be unfamiliar to us. And I think that as doctors and writers, we do often feel obliged to tell their stories from the mountaintops, to let other people in on some of the aspects of life and medical care that they're going through and just how inspiring some of these patients can be. Harshil Vangipuram: Yeah, yeah, very true. Very true. Mikkael Sekeres: You mentioned that your mom is a medical oncologist. What kind of influence did she have on your decision to enter medicine and perhaps your own specialty one day? Harshil Vangipuram: Observing my mother practice influenced a lot, and she taught me that medicine is not only about treating a patient, but also listening to their problems. It may be more present in the room. The textbooks I read didn't capture live experiences. I always thought that stories will stay with people longer than actual survival curves. Writing filled that gap between what I studied and what I felt in the OPD. Mikkael Sekeres: It's a great phrase you just whipped out. Patients' stories will stay with us longer than survival curves. Can you tell us a little bit about where her clinic is located? You said in southern India. Can you describe the types of patients she sees? Harshil Vangipuram: It's a small town called Nellore in Andhra Pradesh state. The patients are, most of the time, from a rural population where decisions are mostly family-driven and there's a tight community surveillance and the stigmas are more overt, too. A few of them can be from urban population also, but they have subtler discriminations towards stigmas. Mikkael Sekeres: Can you explain a little further what you mean by decisions are often family-driven? Harshil Vangipuram: If we take marriage, it is often seen as an alliance between two families that are trying to increase their social value, their economic status, and respect in the society. In arranged marriages, for suppose, it's basically driven between these concepts. Mikkael Sekeres: I don't know if it's too personal to ask, but are your parents in an arranged marriage? Harshil Vangipuram: No, not at all. Mikkael Sekeres: So not all the marriages in the clinic are arranged marriages. Harshil Vangipuram: Yeah. Mikkael Sekeres: You know, when you said that decisions are family-driven, you mentioned that people are in arranged marriages. And I wanted to talk a little bit about the stigma you highlight in your essay. I'll talk about that in a second. I thought you were going to go down a route about medical decisions being family-driven, meaning people have to support their families, and getting medical care is costly and takes time away from work, and that sometimes influences decisions about treating cancer. What examples have you seen of that in shadowing your mom? Harshil Vangipuram: I have seen patients who have Hodgkin's lymphoma, breast cancer, and ovarian cancer, who were in the age of 25 to 35, who were getting married. Many of them actually got their engagements broken. And many of them got rejected at matrimonial apps. Many of them also had been told to increase the dowry that is given actually in the form of financial security. Mikkael Sekeres: In your essay, you describe a woman who is engaged and who has a new diagnosis of Hodgkin lymphoma. Can you talk a little bit about the process of getting engaged and marrying in southern India? Harshil Vangipuram: We have the arranged marriage, love marriage, and hybrid, which is kind of arranged and kind of in love. Mostly, these problems really occur in arranged marriages. In love marriages, we don't see that that often because both are understanding about themselves and their families. And both families actually accept them both. Mikkael Sekeres: What's the process of going through an arranged marriage? What happens? Harshil Vangipuram: It can be through parents, relatives, or any known ones or through peers. We just find a man or woman who has a similar caste, who has a good financial income, and people who are respected by the society. And obviously, both the families should have aligned interests for them to accept the marriage. Mikkael Sekeres: About how often are marriages arranged and how often are they love marriages in southern India where you live? Harshil Vangipuram: Almost 90% of the marriages are arranged here. Mikkael Sekeres: Wow. So, your parents were unusual then for having a love marriage. Harshil Vangipuram: Yeah. Mikkael Sekeres: In your essay, you write, and I'm going to quote you now, "Among young, unmarried women in India, survivorship often came with a parallel challenge of navigating shifts in how they were perceived, particularly as marriage prospects. In Indian families where marital status is closely tied to stability and future security, a woman with a cancer history, even after complete remission, somehow came to be quietly perceived as less suitable." Wow, that's a really moving statement. I'm curious, what stories have you seen where, in your words, women became less suitable as a marriage prospect? Harshil Vangipuram: For women, the most important thing in a marriage is, what do you call, a family honor, fertility, and economic status in the community. So, after a long dose of chemo, many people think that people become infertile. In India, basically, we have many misconceptions and stigmas. So, people obviously think that people who have got cancer can spread it to their children or are infertile and are often excluded out of the society as a marriage prospect. Mikkael Sekeres: Gosh, that must be devastating. Harshil Vangipuram: Yeah. Mikkael Sekeres: Does the same occur for men? So, is it also true that if a man has cancer, that he is perceived as less fertile, or it may be perceived that he can pass the cancer on to children? Harshil Vangipuram: Here, after a man beats cancer, they start to celebrate it, like they have achieved something, and it's not like that for a woman. Mikkael Sekeres: In your essay, you do write about a happy ending for one woman. Can you tell us about that? Harshil Vangipuram: Yeah, a cancer survivor obviously met her true love of life in Bengaluru, who was an ENT resident then. And his father died from lung cancer. So obviously, he knew what it felt to beat cancer. Mikkael Sekeres: Yeah, he'd been through it himself. And the irony, of course, is that most cancer treatments that we give do not lead to infertility, so it's a complete misperception. Harshil Vangipuram: Yeah. Mikkael Sekeres: Tell us about your future. What are the next steps for you in your training and what do you hope to specialize in and practice? Harshil Vangipuram: Actually, I'm working on another paper which involves financial toxicity after treatment and post treatment depression. I think it would be completed in another year. And after that, after my med school is completed, I think I'm going to pursue oncology or hematology as my branch of interest. Mikkael Sekeres: Wonderful. It's thrilling to hear that somebody who is as sensitive to his patients and both their medical needs and their needs outside of medicine will be entering our field. It'll be great to know that you'll be taking care of our future patients. Harshil Vangipuram: The pleasure is all mine, sir. Mikkael Sekeres: Harshil Vangipuram, I want to thank you for choosing JCO Cancer Stories: The Art of Oncology and for submitting your great piece, "Whispers After the Cure: Reflections on Marriage and Malignancy in India" to JCO Global Oncology. To our listeners, if you've enjoyed this episode, consider sharing it with a friend or colleague or leave us a review. Your feedback and support helps us continue to have these important conversations. If you're looking for more episodes, follow our show on Apple, Spotify, or wherever you listen, and explore more from ASCO at asco.org/podcasts. Until next time, this has been Mikkael Sekeres from the Sylvester Cancer Center, University of Miami. Have a good day. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Show notes:Like, share and subscribe so you never miss an episode and leave a rating or review. Guest Bio:Dr Vangipuram Harshil Sai is a fourth semester medical student at All India Institute of Medical Sciences. Additional Reading Impact of Gender of the Child on Health Care–Seeking Behavior of Caregivers of Childhood Patients With Cancer: A Mixed-Methods Study | JCO Global Oncology

Donate (no account necessary) | Subscribe (account required) Join Bryan Dean Wright, former CIA Operations Officer, as he dives into today's top stories shaping America and the world. In this episode of The Wright Report, we cover Jimmy Kimmel's controversial return to television, a Supreme Court ruling that could reshape presidential power, the growing struggles of America's farmers and truckers, and new White House warnings about Tylenol and autism. From free speech fights to medical debates, today's brief connects culture, politics, and science shaping America's future.   Jimmy Kimmel Returns to Air with FCC Debate: Disney announced Kimmel would return, calling his remarks “ill-timed and insensitive” but not admitting his claims about Charlie Kirk's assassin were lies. Sinclair caved after death threats, canceling a Kirk tribute and airing Kimmel again. Senators Rand Paul and Ted Cruz blasted Trump's FCC for even raising news distortion, with Cruz comparing it to “Goodfellas.” Bryan warned, “We cannot sit down with the modern Democrat party… they assassinate people who get in the way — like Charlie Kirk.”   Supreme Court Expands Presidential Power: In a 6–3 decision, the Court allowed Trump to fire a Democrat FTC commissioner while hearing the full case in December. The ruling challenges the 1935 precedent limiting executive power. Bryan explains it could restore Jefferson-style authority, including presidential impoundment of spending. “Welcome to the new version of American democracy… it's a bit of a mess right now.”   Farmers, Ranchers, and Truckers Under Pressure: New screwworm cases in northern Mexico threaten U.S. cattle herds already at historic lows. Soybean farmers face collapse as Xi stops buying American crops, while truckers lose money under depressed rates and costly California regulations. Bryan calls for revoking visas of foreign drivers who “can't read or speak English and are killing people on the road.”   White House Links Tylenol to Autism: Trump's HHS and FDA advised pregnant women to limit acetaminophen after new studies showed it can cross the placenta, cause oxidative stress, and disrupt brain development. Critics called the claims weak, but Bryan compared it to past medical dogmas debunked by Dr. Barry Marshall, who proved ulcers were caused by bacteria: “Quite literally the entire world of Medical Science was wrong. That one doctor was right.”   "And you shall know the truth, and the truth shall make you free." - John 8:32     Keywords: Jimmy Kimmel FCC news distortion, Rand Paul Ted Cruz Goodfellas FCC quote, Sinclair cancels Charlie Kirk tribute, Supreme Court Trump FTC ruling, presidential impoundment Jefferson precedent, U.S. screwworm outbreak Nuevo Leon, U.S. soybean farmers China ban, trucker wages California EV mandate, Trump revoke foreign trucker visas, Trump HHS FDA Tylenol autism warning, acetaminophen oxidative stress fetus, Dr. Barry Marshall ulcer Nobel Prize

"Jung was essentially an evolutionary theorist". These are the words of Gary Clark, a Visiting Research Fellow in the School of Medical Sciences at the University of Adelaide in Australia, who has written a book on the intersection of Jungian Analytical Psychology and evolutionary neuroscience. If you want to learn more about Gary you can check out his book "Carl Jung and the Evolutionary Sciences: A New Vision for Analytical Psychology" (and grab a free PDF of its intro) here. You can also dive into the rest of his work on academia.edu and ResearchGate. In this conversation, I sit down with Gary to explore the intersection of Jungian psychology and evolutionary neuroscience, examining how recent psychedelic research provides empirical validation for Jung's theories about the collective unconscious and archetypes. We discuss how modern neuroscience, particularly studies of primary and secondary consciousness systems, maps onto Jung's framework of ego consciousness versus deeper archetypal layers. The conversation covers the revolutionary potential of psychedelic research for studying previously inaccessible aspects of consciousness and Jung's prescient evolutionary approach to depth psychology.⏳Timestamps00:00 James's Intro01:07 Opening and situating Gary's work03:35 Affective Neuroscience and the Primary and Secondary layers of consciousness09:00 Psychedelics, the numinous and evolutionary theory22:17 Have we found the (neuroscientific) archetypes?28:40 Psychedelics and the Collective Unconscious34:53 Jordan Peterson's Jungian synthesis36:57 Peterson gets chimpanzees and ancient humans wrong46:01 Leaving Jung behind: Depth Psychology maturation as a science58:50 Mapovers between Iain McGilchrist's work and Gary's1:01:19 What Gary's working on now1:07:32 Gary's guest recommendation: Erik Goodwyn

In this episode, I dive into the complexities of autoimmunity and the gut-brain axis with Dr. Datis Kharrazian, one of the leading voices in functional medicine. What strikes me about our conversation is how he connects the dots between environment, genetics, and lifestyle, painting a clear picture of why autoimmune diseases are on the rise and why they're so difficult to treat. Dr. Kharrazian breaks down how and why the immune system malfunctions, and more importantly, how lifestyle adaptations can play a pivotal role in managing these conditions. Together, we explore the principles of functional medicine and how they reshape chronic disease care, while also looking at the latest insights into the gut microbiome, its impact on brain health, and the links to conditions like Alzheimer's and long COVID. This episode is packed with professional insights, practical takeaways, and a vision of how functional medicine can transform patient care in today's world. Key Takeaways: Autoimmunity occurs when the immune system mistakenly attacks the body's own tissues, with factors such as environmental exposure and genetic susceptibility being key contributors. Functional medicine prioritizes enhancing bodily functions rather than simply inhibiting disease symptoms, offering a promising approach for managing chronic diseases. Lifestyle factors like sleep, stress management, and exercise play a crucial role in managing autoimmune conditions and maintaining overall health. The gut-brain axis is integral to understanding and treating neurological conditions, with bidirectional communication between these systems influencing health outcomes. Precision diagnostics and individualized care models are essential for effective functional medicine practice, emphasizing the need for education in the field. Dr. Datis Kharrazian is a clinical research scientist, academic professor, and a functional medicine healthcare provider. He is an Associate Clinical Professor at Loma Linda University School of Medicine. Dr. Kharrazian earned a PhD in Health Science with concentrations in immunology and toxicology, and a Doctor of Health Science degree from Nova Southeastern University. He also holds a Master of Science degree in Human Nutrition from the University of Bridgeport, a Doctor of Chiropractic degree from Southern California University of Health Sciences, and a Master of Medical Sciences degree in Clinical Investigation from Harvard Medical School. Dr. Kharrazian completed his post-doctoral research training at Harvard Medical School and Massachusetts General Hospital. He was a researcher at Harvard Medical School for seven years. Currently, he serves as the academic director of the Kharrazian Institute and the Academy of Functional Nutrition and Lifestyle Medicine. Website The Academy of Functional Nutrition and Lifestyle Medicine Instagram Connect with me! Website Instagram Facebook YouTube

Meet Christina Boylston—a Functional Diagnostic Nutrition Practitioner with a Master's in Medical Sciences and over a decade of experience in preventative and regenerative medicine. From battling undiagnosed Hashimoto's and postpartum complications to regaining her energy through functional lab testing, this conversation dives deep into the root causes of exhaustion and burnout for moms.   Want to watch this episode on YouTube? Click here. Subscribe if you'd like to catch all new episodes live and participate with our guests directly.   Want to learn more about becoming an FDN? Go to fdntraining.com/resources to get our best free workshops and mini-courses! Where to find Christina Boylston: Website: layerstowellness.com Instagram: @christina_boylston Facebook: @christina.boylston  

What if hair loss was really a signal from your body, not just a cosmetic issue?In this episode, I talk with VJ Hamilton, The Autoimmune Nutritionist, about overcoming alopecia areata and other forms of hair loss by addressing root causes. We dive into nutrient deficiencies, gut health, thyroid imbalances, and inflammation and how functional medicine can help hair grow back naturally.If you've been told there's no hope for hair loss, this episode will challenge that belief.Episode Timeline: 00:00 – Episode Preview02:07 – Podcast Intro02:32 – Meet VJ Hamilton, Autoimmune Nutritionist04:02 – VJ's Story: Alopecia at Age 705:24 – Reversing Fatigue, Psoriasis, and Chronic Issues08:55 – Hair Loss: Autoimmune vs. Other Causes12:58 – Hair Regrowth: Healing Timeline16:09 – Inflammation Triggers: Gut, Scalp, Whole Body18:12 – Five Key Hair Loss Markers25:44 – Biotin: Overrated or Essential?27:50 – Nutrients: Selenium, Vitamin A, Genetics31:29 – Low Stomach Acid and Absorption33:01 – Supplements vs. Food for Hair Growth35:05 – First Steps with Hair Loss Diagnosis36:07 – Complex Cases: Mold, Toxins, Nervous System39:25 – Connect with VJ Hamilton Online40:42 – Podcast Outro41:03 – Root Cause Healing: Final TakeawaysAbout VJ Hamilton:VJ Hamilton, also known as The Autoimmunity Nutritionist, is the founder of The Autoimmune Nutrition Clinic and a Registered Nutritionist specialising in reversing hair loss, particularly alopecia areata, and other autoimmune-related conditions. With a Medical Science degree (BSc) in Biochemistry & Immunology and certification from the Institute for Functional Medicine, VJ combines scientific expertise with lived experience to deliver evidence-based, personalised therapies. Connect with VJ Hamilton:VJ Hamilton's Website: https://theautoimmunitynutritionist.com VJ Hamilton's FB Page: https://www.facebook.com/A.Nutritionist/ To take the Save My Thyroid Quiz visit www.savemythyroid.com/quiz Free resources for your thyroid health Get your FREE Thyroid and Immune Health Restoration Action Points Checklist at SaveMyThyroidChecklist.com High-Quality Nutritional Supplements For Hyperthyroidism and Hashimoto' sHave you checked out my new ThyroSave supplement line? These high-quality supplements can benefit those with hyperthyroidism and Hashimoto's, and you can receive special offers, along with 10% off your first order, by signing up for emails and text messages when you visit ThyroSave.com. Do You Want Help Saving Your Thyroid? Click Here to access hundreds of free articles and blog posts. Click Here for Dr. Eric's YouTube channel Click Here to join Dr. Eric's Graves' disease and Hashimoto's group Click Here to take the Thyroid Saving Score Quiz Click Here to get all of Dr. Eric's published booksC...

Erika Barber sits down with Erika McCarthy, physician assistant and professor, to explore one of the most pressing questions in healthcare today: Faith vs. Science — can they truly coexist in medicine?This conversation is for anyone curious about the intersection of faith, ethics, and modern medicine: How does grief shape the way medical providers care for patients? What role does hope play in healing? Should spiritual perspectives influence medical education and clinical practice? And what does it look like for healthcare providers to care for the whole person — mind, body, and spirit?Together, they share personal stories of loss, moments of hope, and the ways their Christian faith continues to shape their approach to medicine, education, and patient care.Erika McCarthy is an Assistant Professor of Medical Science at George Fox University. Dr. Erika Barber teaches in George Fox University's physician assistant program and holds board certification in internal medicine and geriatrics.

In this episode, Mason sits down with Dr. Carol Haddad to explore a topic close to the hearts of so many—how traditional medical treatments and complementary approaches can work together for deeper healing. Instead of choosing one path over the other, Dr. Carol shares how integration creates a more personalized, compassionate, and effective journey toward wellness. You'll hear real-world examples, practical strategies, and encouraging insights that remind us healing isn't just about treating the body—it's about nurturing the whole person: mind, body, and spirit. Whether you're a patient, caregiver, or simply curious about integrative approaches, this conversation offers hope, wisdom, and a refreshing perspective on what's possible when different worlds of medicine come together. By the end of this episode, you'll feel empowered with new ways to think about health, inspired by stories of resilience, and encouraged to see healing as more than a diagnosis—it's a journey.   Key Insights & Timestamps 02:15 The importance of blending science with holistic approaches 05:42 Why patients shouldn't feel forced to choose “either/or” in treatment 09:10 Dr. Carol's story of how she embraced integrative care 14:27 The role of nutrition and lifestyle in healing 18:55 How mindset and emotional health impact physical recovery 23:40 The science behind complementary therapies 28:05 Stories of patients who found strength through integrative care 33:12 How caregivers can support the journey with compassion 38:46 The future of medicine: collaboration over competition 42:19 Practical steps to begin your own integrative path About Dr. Carol Haddad Dr. Carol is a highly trained physician who bridges the gap between conventional oncology and holistic healing. With a background that includes a Medical Science degree from UNSW, a postgraduate degree in Medicine from the University of Sydney, specialty training in Radiation Oncology, and certification in Functional Medicine, she has more than a decade of experience treating patients within hospital and cancer center settings. Her journey led her beyond traditional medicine into the world of integrative oncology, where she combines evidence-based treatments with complementary therapies such as natural medicine, psycho-energetic healing, nutrition, and lifestyle interventions. This unique approach allows her to deliver truly holistic cancer care—addressing not just the disease, but the whole person. Dr. Carol believes that patients deserve a more balanced model of treatment, one that draws from the strengths of both science and spirituality to improve outcomes and quality of life. Today, she consults with patients and healthcare professionals worldwide, offering guidance on functional medicine, integrative cancer strategies, and ways to minimise side effects while maximising recovery. Her mission is to empower individuals to embrace long-term wellbeing, reduce recurrence risk, and experience healing in a more sustainable way. If you're curious about functional medicine, holistic oncology, or integrative cancer support, this episode is for you.   Resources Mentioned: Email: drcarolhaddad@gmail.com Website: www.drcarolhaddad.com

Founding director of the Doctor of Medical Science program at The College of St. Scholastica, Kenneth Botelho, discusses his article, "In the absence of physician mentorship, who will train the next generation of primary care clinicians?" Kenneth highlights the accelerating crisis caused by the erosion of physician mentorship, particularly impacting physician associates (PAs) in primary care who historically relied on close, hands-on guidance. He explains that with an aging physician workforce and doctors leaving primary care, this traditional apprenticeship model is breaking down, leaving many new PAs with minimal supervision and high-pressure roles, increasing risks of burnout and clinical error. Kenneth argues that while the old system cannot be revived, innovative solutions like postgraduate PA fellowships and residencies, supported by Doctor of Medical Science (DMSc) programs, offer a path forward. He details how these programs can create a new pipeline of PA leaders equipped with advanced clinical competence, leadership skills, and an understanding of value-based care and health care economics, enabling them to fill mentorship gaps and improve a strained health care system. Kenneth stresses that this is a system issue requiring bold, collaborative action to support learners and ensure patient safety. Our presenting sponsor is Microsoft Dragon Copilot. Microsoft Dragon Copilot, your AI assistant for clinical workflow, is transforming how clinicians work. Now you can streamline and customize documentation, surface information right at the point of care, and automate tasks with just a click. Part of Microsoft Cloud for Healthcare, Dragon Copilot offers an extensible AI workspace and a single, integrated platform to help unlock new levels of efficiency. Plus, it's backed by a proven track record and decades of clinical expertise—and it's built on a foundation of trust. It's time to ease your administrative burdens and stay focused on what matters most with Dragon Copilot, your AI assistant for clinical workflow. VISIT SPONSOR → https://aka.ms/kevinmd SUBSCRIBE TO THE PODCAST → https://www.kevinmd.com/podcast RECOMMENDED BY KEVINMD → https://www.kevinmd.com/recommended